WO2025233286A2 - Utilisation d'arca et d'enzyme 2'o-méthyl transférase pour produire une structure cap1 d'une coiffe d'arnm 5' - Google Patents

Utilisation d'arca et d'enzyme 2'o-méthyl transférase pour produire une structure cap1 d'une coiffe d'arnm 5'

Info

Publication number
WO2025233286A2
WO2025233286A2 PCT/EP2025/062232 EP2025062232W WO2025233286A2 WO 2025233286 A2 WO2025233286 A2 WO 2025233286A2 EP 2025062232 W EP2025062232 W EP 2025062232W WO 2025233286 A2 WO2025233286 A2 WO 2025233286A2
Authority
WO
WIPO (PCT)
Prior art keywords
rna polymerase
mrna
rna
reaction
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/062232
Other languages
English (en)
Other versions
WO2025233286A3 (fr
Inventor
Justinas SLIKAS
Egle KOMAROVEC
Domas RUPKUS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thermo Fisher Scientific Baltics UAB
Original Assignee
Thermo Fisher Scientific Baltics UAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thermo Fisher Scientific Baltics UAB filed Critical Thermo Fisher Scientific Baltics UAB
Publication of WO2025233286A2 publication Critical patent/WO2025233286A2/fr
Publication of WO2025233286A3 publication Critical patent/WO2025233286A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01057—Methyltransferases (2.1.1) mRNA (nucleoside-2'-O-)-methyltransferase (2.1.1.57)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)

Definitions

  • the invention lies in the field of mRNA synthesis during in vitro transcription (IVT), a procedure allowing for template-directed synthesis of RNA molecules including capping of the synthesized mRNA for increased mRNA stability.
  • IVT in vitro transcription
  • RNAs eukaryotic messenger RNAs
  • mRNAs eukaryotic messenger RNAs
  • viral RNAs include a 5'-cap structure (“capO") found at the 5' end of the RNA that consists of a N7-methylguanosine nucleoside linked to the 5'-terminal nucleoside of the pre-mRNA via a 5'-5' triphosphate linkage.
  • the "capO" structure is critical for recognition by the translation factor elF4E protein and mRNA translation into proteins by ribosomes, as well as for protection from degradation by 5' exonucleases.
  • RNA capping is important for other processes, such as RNA splicing and export from the nucleus.
  • cap 2'0 methylation As an identifier of self RNA to avoid recognition of mRNA by the cellular innate immunity machinery.
  • Such 2'0 methylation is located at the first (+1) nucleotide adjacent to the cap structure at the 5' end of the RNA and is thus called a "capl" structure.
  • IVT in vitro transcription
  • RNA DNA-dependent ribonucleic acid
  • IVT produces uncapped, 5'-triphosphorylated RNA.
  • uncapped RNA can be capped during the transcription reaction in a process called "co-transcriptional capping.”
  • capO mRNA can be produced by treating uncapped, 5'-triphosphorylated RNA post- transcriptionally, using a series of enzymatic steps, in a process called "enzymatic capping" (see, e.g., Muttach et al., J. Org Chem.
  • a common method for enzymatic capping includes a series of three enzymatic reactions in which the 5'-triphosphate terminus of a primary transcript is first cleaved to a diphosphate by RNA triphosphatase, then capped with GMP by RNA guanylyltransferase, and methylated at the N7 position of guanine by RNA (guanine-7)- methyltransferase.
  • a cap analog is added to the RNA during the IVT reaction in order to generate capO-type mRNA.
  • CapO-type mRNAs whether produced by enzymatic or co-transcriptional capping, can be subsequently methylated at the 2'0 position of the nucleotide 3' to the N7-methylguanosine, thereby generating an mRNA having a capl structure.
  • Such protocols are, however, laborious and time consuming.
  • the present invention is based in part, on the surprising discovery that capl-type capped mRNA can be achieved in a single reaction, wherein co-transcriptional capping is combined with 2'0 methylation at the +1 position of the RNA in one single reaction. Accordingly, the present invention advantageously enables the production of capped mRNA having a capl structure from DNA in a single reaction step, making the synthesis of capl faster and more economical. Moreover, the yield of capped mRNA having a capl structure is increased using the present inventive methods compared to the two-step protocol widely used in the prior art.
  • the present invention refers to a method of synthesizing capped mRNA.
  • the method includes combining (i) a nucleic acid template comprising a target sequence to be transcribed and an RNA polymerase promoter site operably linked upstream to the target sequence, (ii) an RNA polymerase capable of binding the promoter site, (iii) a transcription buffer, (iv) ribonucleoside triphosphates (NTPs), (v) a dinucleotide cap analog according to Formula I wherein R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl; R 2 is H, OH or O-CH3; R 3 is H, OH or O-CH3; R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se; R 7 and R 8 are OH
  • the components of the composition are combined in a single vessel.
  • the composition produced is an IVT reaction mixture.
  • an in vitro transcription (IVT) of the nucleic acid template is performed during the incubation step.
  • the composition may further comprise an RNase inhibitor.
  • the composition may further comprise a pyrophosphatase.
  • the composition may further comprise polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the composition may further comprise an RNase inhibitor, a pyrophosphatase, and/or PEG.
  • At least one of R 2 or R 3 of the dinucleotide cap analog is O-CH3.
  • R 2 may be OH and R 3 may be O-CH3.
  • IVT, co-transcriptional mRNA capping and methylation of capped mRNA may be performed simultaneously.
  • the methylation of capped mRNA is performed without prior mRNA purification.
  • the RNA polymerase may be selected from the group comprising T7, SP6, or T3, Vsw-3, Kll, T3D, T5, T8, (02.5, (06 RNA polymerase or a functional variant thereof, or any combination thereof.
  • the RNA polymerase is a T7, SP6, or T3 RNA polymerase.
  • the RNA polymerase is a T7 RNA polymerase.
  • the GTP may be present in a ratio GTP: dinucleotide cap analog from 1:1 to 1:10.
  • the GTP may be present in a ratio GTP: dinucleotide cap analog from 1:1 to 1:8.
  • the GTP may be present in a ratio GTP: dinucleotide cap analog of 1:4.
  • the ribonucleotides may comprise ATP, CTP, UTP and GTP, or any modified ribonucleotide.
  • the ribonucleotides may alternatively be ATP, CTP, UTP and GTP.
  • the nucleic acid template may be a DNA template selected from the group consisting of a plasmid, a PCR product, cDNA, a double-stranded (ds)oligonucleotide, or a dsDNA comprising covalently closed ends.
  • the nucleic acid template may be a plasmid.
  • the nucleic acid template may be a PCR product.
  • the nucleic acid template may be a cDNA.
  • the nucleic acid template may be a (ds)oligonucleotide.
  • the nucleic acid template may be a dsDNA comprising covalently closed ends.
  • the nucleic acid template is a combination of two or more types of nucleic acid template selected from the group consisting of a plasmid, a PCR product, cDNA, a double-stranded (ds)oligonucleotide, or a dsDNA comprising covalently closed ends.
  • the nucleic acid template is immobilized on a solid support.
  • the nucleic acid template may further comprise a plurality of T nucleotides downstream of the target sequence to be transcribed.
  • the plurality of T nucleotides comprises modified nucleotides or analogues thereof.
  • composition produced in the method may further comprise a poly-A polymerase.
  • the transcription buffer can include a buffering agent, magnesium salts and optionally other salts, a reducing agent and/or additional components.
  • the transcription buffer may comprise MgCL.
  • the transcription buffer may comprise DTT.
  • the transcription buffer may comprise spermidine.
  • the transcription buffer may comprise NaCI.
  • the transcription buffer comprises MgCh, DTT and spermidine.
  • the transcription buffer comprises NaCI, MgCL, DTT and/or spermidine.
  • the 2'0-methyl transferase may be derived from vaccinia virus.
  • the yield of mRNA comprising capl-type structure is in the range of 95-100%.
  • the %-amount of synthesized mRNA comprising capl-type structure is in the range of 95-100%.
  • greater than 95% of the synthesized mRNA comprises a capl-type structure.
  • the 2'-O-methyltransferase and/or RNA polymerase may be immobilized on a solid support.
  • the method is an in vitro method.
  • the invention refers to a composition for use in the synthesis of capl-type mRNA from a nucleic acid template, the composition comprising RNA polymerase, transcription buffer, ribonucleoside triphosphates (NTPs), dinucleotide capping primer according to Formula I wherein wherein R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl; R 2 is H, OH or O-CH3; R 3 is H, OH or O-CH3; R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se; R 7 and R 8 are OH; n is 1, 2, or 3; and B is a non-modified or modified purine or pyrimidine base; the composition further comprises a 2'-O- methyltransferase, and S-adenosylme
  • the composition is suitable for long term storage. In an embodiment, the composition is stable for about 1-10 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 1-5 months, 1-6 months.
  • the composition may further comprise an RNase inhibitor.
  • the composition may further comprise a pyrophosphatase.
  • the composition may further comprise polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the composition may further comprise an RNase inhibitor, a pyrophosphatase, and/or PEG.
  • At least one of R 2 or R 3 of the dinucleotide cap analog is O-CH3.
  • R 2 may be OH and R 3 may be O-CH3.
  • the RNA polymerase may be selected from the group comprising T7, SP6, or T3, Vsw-3, Kll, T3D, T5, T8, (02.5, (06 RNA polymerase or a functional variant thereof, or any combination thereof.
  • the RNA polymerase is a T7, SP6, or T3 RNA polymerase.
  • the RNA polymerase is a T7 RNA polymerase.
  • the GTP may be present in a ratio GTP: dinucleotide cap analog from 1:1 to 1:10.
  • the GTP may be present in a ratio GTP: dinucleotide cap analog from 1:1 to 1:8.
  • the GTP may be present in a ratio GTP: dinucleotide cap analog of 1:4.
  • the ribonucleotides may comprise ATP, CTP, UTP and GTP, or any modified ribonucleotide.
  • the ribonucleotides may alternatively be ATP, CTP, UTP and GTP.
  • composition may further comprise a poly-A polymerase.
  • the transcription buffer comprises a buffering agent, magnesium salts and optionally other salts, reducing agent and/or additional components.
  • the transcription buffer may comprise MgCL.
  • the transcription buffer may comprise DTT.
  • the transcription buffer may comprise spermidine.
  • the transcription buffer may comprise NaCI.
  • the transcription buffer comprises MgCL, DTT and spermidine.
  • the transcription buffer comprises NaCI, MgCL, DTT and/or spermidine.
  • the present invention refers to the use of the above described composition for the synthesis of mRNA therapeutics. In another aspect, the invention refers to the use of the above described composition for the synthesis of mRNA in a bioreactor.
  • the invention refers to the use of the above described composition in an RNA printer.
  • the invention refers to the of the above described composition for the synthesis of mRNA in a continuous flow device or a flow reactor.
  • RNA product refers to the mRNA product of an IVT reaction.
  • DNA template is interchangeable with the term “nucleic acid template”, “polynucleotide template” or “in vitro transcription template” and refers to a preferably doublestranded deoxyribonucleic acid (dsDNA) suitable for use in an IVT reaction for the production of mRNA, i.e., the DNA template can be transcribed in an IVT reaction.
  • DNA templates have a promoter (e.g., a T7, T3 or SP6 promoter) recognized by a cognate RNA polymerase upstream of the region that is transcribed.
  • an IVT template encodes a 5' untranslated region, contains an open reading frame, and encodes a 3' untranslated region and a poly(A/T) tail.
  • the particular nucleotide sequence composition and length of an IVT template will depend on the mRNA of interest encoded by the template.
  • the template can be double-stranded and have a coding and non-coding nucleic acid strand, wherein the mRNA is the equivalent of the coding strand (also often referred to as sense strand or plus strand) and is transcribed from the non-coding template strand (also often referred to as antisense or minus strand).
  • a "3' untranslated region (UTR)” refers to a region of an mRNA that is directly downstream (i.e., 3') from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) and that does not encode a protein or peptide.
  • An "open reading frame” is a continuous stretch of nucleic acid beginning with a start codon and ending with a stop codon and encodes a protein or peptide.
  • Nucleic acid can be DNA or RNA.
  • IVTT in vitro transcription
  • the terms "chemical modification” or, as appropriate, “chemically modified” or alternatively “modified base” refer to modifications with respect to adenosine (A), guanosine (G), uridine (U), thymidine (T) or cytidine (C) ribo- or deoxyribnucleosides and/or the internucleoside linkages in one or more of their position, pattern, percent or population.
  • the modifications may be one or more various distinct modifications.
  • the regions may contain one, two, or more (optionally different) nucleoside or nucleotide modifications and/or internucleoside linkages.
  • a modified polynucleotide introduced to a cell may exhibit reduced degradation in the cell as compared to an unmodified polynucleotide.
  • buffer refers to an agent that allows a solution to resist changes in pH when acid or alkali is added to the solution.
  • buffering agents include, for example, Tris, HEPES, TAPS, MOPS, tricine, or MES.
  • reaction buffer refers to the composition of components where the respective enzymatic reaction takes place.
  • the reaction buffer may also contain one or more of salts, detergents, antifoaming agents, cofactors, reducing agents, additives, etc.
  • cap refers to a non-extendible dinucleotide that facilitates translation or localization, and/or prevents degradation of an RNA transcript when incorporated at the 5' end of an RNA transcript, typically having an m 7 GpppG or m 7 GpppA structure.
  • dinucleotide cap analog refers to a non-extendible dinucleotide that facilitates translation or localization, and/or prevents degradation of an RNA transcript when incorporated at the 5' end of an RNA transcript, typically having an m 7 GpppG or m 7 GpppA structure, for example, m 7 G(5')p3(5')G, in which a guanine nucleotide (G) is linked via its 5'OH to the triphosphate bridge.
  • the 3'-OH group is replaced with hydrogen or OCHa.
  • the dinucleotide cap analog used in the present invention refers to a compound of Formula I, disclosed herein, such as for example, 3'-OMe-m 7 G(5')p3G (ARCA).
  • capO is interchangeable with “capO-type", “cap-0", “capO structure” or”cap-0 structure” and refers to an (eukaryotic) mRNA cap structure at its 5'-terminus.
  • the cap consists of 7- methylguanosine (m 7 G) and a triphosphate bridge, ppp (ps), linking the 5'OH of m 7 G to the 5'OH of the 5'-terminal nucleotide, N, denoted m 7 G(5')pppN (or m 7 G(5')p3N, or m 7 GpppN) (capO structure).
  • capl is interchangeable with “capl-type”, “cap-1”, “capl structure” or “cap-1 structure”, and refers to a capped mRNA having an additional methylation on the 2'0 position of the initiating nucleotide, i.e. the first nucleotide of the transcribed mRNA.
  • Capl refers to m 7 GpppNm-, where Nm denotes any nucleotide with a 2'0 methylation (capl structure).
  • Me is equivalent to "-CH3", i.e. "-OCH3” or “-OMe” and is used as synonyms, and letter “m” denotes a methyl group bound to oxygen atom. Similarly, “Nm” denotes any nucleotide (N) with a 2'0 methylation.
  • the term "ARCA” or "anti-reverse cap analog” refers to a modified cap analog in which the 3'0H group of the m 7 G is replaced with OCH3 (please see the structural formula below).
  • the structure is represented as m2 7,3 O GpppG or m2 7,3 O (5')Gppp(5')G.
  • it refers to a modified cap analog in which the 2'0H group is replaced with 0CH3.
  • the structure is represented as m2 7 - 2 ' °GpppG or m2 7 - 2 ' °(5')Gppp(5')G.
  • Fig. 1 depicts Mass Spectrometry (MS) analysis of 25 nt RNA vs 26 nt ARCA-RNA (ARCA dinucleotide is incorporated instead of a conventional nucleotide, therefore the +1 nt length).
  • the difference in highlighted m/z value depicted on the right hand side directly above and below the horizontal line, is 293.1, corresponding to ARCA incorporation.
  • Fig. 2 shows MS of 26 nt ARCA-RNA vs 2'-0Me-ARCA-RNA.
  • Fig. 3 MS of Sequential reaction. ARCA-RNA (top) compared to a sequential reaction product of IVT and 2OMt treatment (bottom), as described in the method. The difference in m/z value between major peaks corresponds to 2'0-methyl functionality.
  • Fig. 4 MS of Add-on reaction.
  • ARCA-RNA top
  • the Add-on reaction product of IVT and 2OMt treatment bottom
  • the difference in m/z value between major peaks corresponds to 2'0-methyl functionality.
  • Fig. 5 MS of One-pot reaction.
  • ARCA-RNA (top) compared to the One-pot reaction product of IVT and 2OMt treatment of the present invention.
  • the difference in m/z value between major peaks corresponds to 2'0-methyl functionality.
  • Fig. 7 One-pot capping and methylation analysis. Mass spectrometry data analysis comparing the relative abundance of species of corresponding m/z values. Capping efficiency is determined by comparing capped RNA and uncapped RNA. Methylation efficiency is determined by comparing capped RNA and capped, methylated RNA. The methylated fraction is determined by comparing the capped RNA fraction to capped, methylated RNA fraction of the mass spectrum.
  • IVT In vitro transcription
  • a T7 promoter covers the sequence ranging from -17 to +6 with +1 being the first nucleotide of the transcribed region.
  • RNA-dependent ribonucleic acid (RNA) polymerase synthesizes template-derived mRNA transcripts.
  • transcription termination usually intervenes by "run off,” that is when the polymerase falls off at the very end of the template.
  • transcription termination is defined by the ends of the template products.
  • plasmid-based templates this is achieved by linearizing the plasmid by restriction enzyme digestion downstream from the sequence of interest, e.g. as described in Thermo Fisher, 2012, "DNA Template Preparation for in vitro Transcription".
  • RNA transcripts generated from IVT there are two options for adding a cap structure to uncapped RNA transcripts generated from IVT; namely post-transcriptional capping and co-transcriptional capping.
  • post-transcriptional capping uncapped RNA from IVT is subjected to a dedicated enzymatic capping reaction, i.e., the transcription reaction and the capping reaction occur sequentially, and most often in separate reactions requiring different buffering conditions.
  • the resulting capped mRNA has a cap-0 structure.
  • cap analogues are added directly to the IVT reaction, i.e., mRNA cap is incorporated into the mRNA by the RNA polymerase as it transcribes the template nucleic acid.
  • RNA polymerases directly yields the respective 5'-capped mRNA (capO structure that does not contain the 2'-0Me group in the first transcribed nucleotide.).
  • mRNA synthesis consists of at least two reactions, transcription comprising co-transcriptional capping and the 2'0 methylation of the +1 nucleotide making the process error- prone and time consuming.
  • Prior art additionally recommends to purify capped mRNA prior to setting the methylation reaction.
  • the present invention provides an improved method to synthesize capped mRNA having a capl structure compared to methods known in the art.
  • a method for synthesizing capped mRNA wherein transcription, co-transcriptional capping and 2'0 methylation is performed in one reaction.
  • a "one pot" solution is provided for the synthesis of capped mRNA from DNA, the cap having a capl structure.
  • the present invention provides for a simple and rapid method of capped mRNA synthesis with a maximum yield of capped mRNA (capl structure) of preferably 99% to 100%.
  • the present method achieves higher yields of successfully capped mRNA (capl structure) then methods known from the art.
  • the invention relates to a method of synthesizing capped mRNA.
  • the method comprises providing a nucleic acid template comprising a target sequence to be transcribed and an RNA polymerase promoter site operably linked upstream to the target sequence.
  • the method comprises providing nucleic acid template, an RNA polymerase capable of binding the promoter site, a transcription buffer, ribonucleotide triphosphates (NTPs), a 2'-O-methyl transferase, S-adenosyl methionine (SAM) and a dinucleotide cap analog according to Formula I wherein R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl; R 2 is H, OH or O-CH3; R 3 is H, OH or O-CH3; R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se; R 7 and R 8 are OH; n is 1, 2, or 3; and B is a non-modified or modified purine or pyrimidine base.
  • NTPs ribonucleotide triphosphates
  • RNA in vitro transcription reactions are usually performed as batch reactions in which all components are combined and then incubated to allow the synthesis of RNA molecules until the reaction terminates. Additionally, fed-batch reactions were developed to increase the efficiency of the RNA in vitro transcription reaction (Kern et al. (1997) Biotechnol. Prog. 13: 747-756; Kern et al. (1999) Biotechnol. Prog. 15: 174-184). In a fed-batch system, all components are combined, but then additional amounts of some of the reagents are added over time (e.g., NTPs, magnesium salts, etc.) to maintain constant reaction conditions. The one pot solution of the invention thus allows for large scale batch and fed-batch reactions.
  • RNA molecules by in vitro transcription
  • the bioreactor is configured such that reactants are delivered via a feed line to the reactor core and RNA products are removed by passing through an ultrafiltration membrane (having a nominal molecular weight cut-off, e.g., 100,000 Da) to the exit stream.
  • an ultrafiltration membrane having a nominal molecular weight cut-off, e.g., 100,000 Da
  • the nucleic acid template for transcription is a DNA template selected from the group consisting of a plasmid, a PCR product, cDNA, a double-stranded oligonucleotide or a double-stranded DNA comprising covalently closed ends.
  • the nucleic acid template for transcription is a plasmid.
  • the nucleic acid template for transcription is a PCR product.
  • the nucleic acid template for transcription is a cDNA.
  • the nucleic acid template for transcription is a (ds)oligonucleotide.
  • the nucleic acid template for transcription is a dsDNA with covalently closed ends.
  • the nucleic acid template for transcription is a PCR product that has the promoter (e.g., T7 promoter) as part of the 5' -oligonucleotide used in the PCR reaction.
  • promoter e.g., T7 promoter
  • the nucleic acid template for transcription is a double-stranded oligonucleotide that carries the T7 promoter sequence and the template to be transcribed.
  • a double-stranded oligonucleotide template may be synthesized de novo by chemical or enzymatic synthesis using methods known in the art such as those described for example in WO2017062343 Al.
  • the nucleic acid template for transcription is a cDNA that carries the T7 promoter sequence and the template to be transcribed.
  • the promoter comprised in the nucleic acid template for controlling in vitro transcription can be any promoter for any DNA dependent RNA polymerase.
  • Promoter sequences are nucleic acid sequences (either naturally occurring, produced synthetically or a product of a restriction digest) that are specifically recognized by an RNA polymerase that recognizes and binds to that sequence and initiates the process of transcription whereby RNA transcripts are generated.
  • the promoter sequence has high binding affinity for its respective RNA polymerase, preferably bacteriophage-derived RNA polymerases.
  • the promoter is a bacteriophage-derived promoter.
  • the promoter is a T7, T3 or SP6 RNA polymerase promoter.
  • the promoter is a T7 RNA polymerase promoter.
  • the promoter is a T3 RNA polymerase promoter.
  • the promoter is an SP6 RNA polymerase promoter.
  • the promoter is derived from E. coli.
  • the promoter is a G-initiating promoter.
  • the promoter is an A-initiating promoter.
  • RNA polymerase promotor site is linked upstream to the target sequence. Linking such promoter site to a target sequence is routine in the art.
  • the nucleic acid template further comprises a plurality of thymidine nucleotides downstream of the target sequence to be transcribed.
  • the nucleic acid template is a DNA template comprising a plurality of thymidine nucleotides downstream of the target sequence to be transcribed. This means that the double-stranded DNA template contains a poly (A/T) sequence downstream of the target sequence (i.e. the coding/sense strand comprises a poly A sequence and the non-coding/antisense or template strand comprises a poly T sequence).
  • the nucleic acid template strand may comprise at least 50 T nucleotides, at least 60 T nucleotides, at least 70 T nucleotides, at least 80 T nucleotides, at least 90 T nucleotides, at least 100 T nucleotides, at least 110 T nucleotides, at least 120 T nucleotides, at least 130 T nucleotides, at least 140 T nucleotides, at least 150 T nucleotides, at least 160 T nucleotides, at least 170 T nucleotides, at least 180 T nucleotides, at least 190 T nucleotides, at least 200 T nucleotides, at least 225 T nucleotides, at least 250 T nucleotides
  • the poly (A/T) stretch comprises cytosine residues (see, for example Legnini, I., Alles, J., Karaiskos, N. et al., FLAM-seq: full-length mRNA sequencing reveals principles of poly(A) tail length control, Nat Methods 16, 879-886 (2019)).
  • adenine in poly-A/T stretch may be modified (see, for example Strzelecka D. et al., RNA. 2020 Dec; 26(12): 1815-1837. Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression).
  • the poly-A/T stretch comprises poly-A/T analogs (see, for example Perzanowska O., et al 2022. Chemically Modified Poly(A) Analogs Targeting PABP: Structure Activity Relationship and Translation Inhibitory Properties. Chemistry - A European Journal Volume 28, Issue 42 e202201115).
  • the nucleic acid template is immobilized on a solid support.
  • the nucleic acid template is a DNA template, and the DNA template is immobilized on a solid support.
  • the immobilization of the DNA template allows repeated use of the template and reduces contamination of the RNA product by residual DNA.
  • immobilization makes the use of DNA expendable for the removal of the DNA template from the final RNA product.
  • enzymes used in a method of synthesizing capped mRNA are immobilized on a solid support. Enzyme immobilization methods are known in the art (e.g. as described in WO2016193226A1).
  • RNA polymerase is immobilized on a solid support.
  • 2'-O-methyltransferase is immobilized on a solid support.
  • solid support refers to each undissolved support that is capable of immobilizing a DNA molecule or enzyme or other reaction component on its surface.
  • the solid support material is non-degradable and can be selected from agarose, modified agarose, sepharose, thiopropyl-sepharose, sephadexTM, polystyrene, latex, cellulose and ferro- or ferrimagnetic particles, acrylamide, nitrocellulose, glass, gold, polyethylene vinyl acetate, polypropylene, polymethacrylate, polyethylene, polyethylene oxide, polysilicates, polycarbonates, Teflon, fluorocarbons, nylon, silicon rubber, polyanhydrides, polyglycolic acid, polyactic acid, polyorthoesters, functionalized silane, polypropylfumerate, collagen, glycosaminoglycans, polyamino acids, or any combination thereof.
  • a solid support may have different shapes, preferable the shape is a slide, a membrane, a matrix, a plate, a chip, a resin or a bead.
  • a solid support may further have holes or depressions to perform reactions at defined locations in an arrayed format on or within the solid support. Reactions on a solid support may be carried out in the presence of one or more additives. Such additives may help to keep beads in suspension or otherwise increase the fidelity of enzymes acting in close proximity to the solid support.
  • the additive may be a chemical compound, a polymer, a polysaccharide, a protein, a chaperon, or any mixture thereof.
  • the immobilization of the DNA template on the solid support can be by means of a covalent or non- covalent bond.
  • immobilization of the DNA template is produced by a non-covalent bond.
  • immobilization of a DNA template on a solid support can occur through a non-covalent biotin-streptavidin interaction.
  • the non-coding strand of the DNA template can be modified with a biotin group at the 5 'end, whose function is to immobilize the DNA strand in a solid support matrix comprising the streptavidin protein.
  • the complementary RNA coding strand of the DNA template may remain non-immobilized.
  • the DNA templates are covalently coupled to the solid support material.
  • the solid support may contain active groups such as NHS, carbodiimide, etc. to allow the coupling reaction with the DNA molecule.
  • the DNA molecule can be coupled to the solid support by direct coupling (for example using functional groups such as amino, sulfhydryl, carboxyl, hydroxyl, aldehyde and ketone groups).
  • the link to the solid support material may involve spacers to optimize the spatial separation of the DNA template from the support.
  • the spacer can be provided by inserting additional nucleotides at the 5 'end of the DNA template.
  • a DNA template may be modified with a ligand for immobilization to a solid support at the 5'-end, the 3'-end, or at an internal nucleotide of a DNA strand.
  • the DNA template may be immobilized on the solid support with the 3' -end of the non-coding strand. The immobilization of the DNA template allows the repeated usage of the template and reduces the contamination of the RNA product by residual DNA.
  • the DNA template can be a double-stranded duplex or a unit that comprises a double-stranded promoter region upstream of a single-stranded RNA coding region.
  • the DNA template may be modified with a ligand for immobilization to a solid support at the 5' end, the 3' end, or at an internal nucleotide of a DNA strand.
  • the solid support is selected from the group comprising a microfluidic chip, a column, a cartridge, a membrane, an array, a bead, a nanoparticle or a resin.
  • the solid support is selected from the group consisting of a microfluidic chip, a column, an array, a bead, a nanoparticle or a resin.
  • the solid support is a bead, wherein the bead is of any convenient dimensions and is constructed from any number of known materials.
  • the bead may be monodisperse. Examples of such materials include inorganic materials, natural polymers, and synthetic polymers.
  • the solid support is a bead, wherein the bead is a magnetic bead or a sepharose bead.
  • the magnetic beads may comprise microparticles or nanoparticles.
  • the magnetic beads may contain iron oxide.
  • magnetic nanoclusters as described in patent application No. GB2210796.5 which is hereby incorporated by reference may be used.
  • the magnetic beads may be selected from DynabeadsTM MyOneTM Silane, DynabeadsTM MyOneTM Carboxylic Acid, DynabeadsTM M-270TM Carboxylic Acid, DynabeadsTM, Oligo(dT)25 magnetic beads (all available from Thermo Fisher Scientific), SpeedBeadTM (General Electric, Boston, MA), BioMagPlus COOHTM and ProMag 1 COOHTM (both Bangs Laboratories, INC Fishers), 4.4 pm fluorescent ferromagnetic beads or 2.0 pm ferromagnetic beads (both available from Spherotech INC Lake Forest, IL), 2 pm beads designated WHM-S001TM or 2 pm beads designated WHM-S002TM (both available from Creative Diagnostics, New York, NY), Silicon Hydroxyl Magnetic Microspheres or Carboxyl Magnetic Microspheres or Oligo(dT) Magnetic Microspheres (available at different nm or pm sizes from VDO Biotech, Suzhou, China), Carboxyl Adembeads (available at 100 nm, 200
  • the DNA template is immobilized on nanoparticles.
  • Nanoparticles include, but are not limited to, metal (e.g., gold, silver, copper and platinum), semiconductor (e.g., CdSe, CdS, and CdS coated with ZnS) and magnetic (e.g., ferromagnetic) colloidal materials. Methods to attach DNA templates to the nanoparticles are known in the art.
  • nanoparticles are attached to a substrate. Nanoparticles with or without immobilized DNA template can be attached to substrates as described in, e.g., Grabar et al., Analyt. Chem., 67, 73-743 (1995); Bethell et al., J. Electroanal.
  • Naked nanoparticles may be first attached to the substrate and DNA templates can be attached to the immobilized nanoparticles.
  • the solid support comprises a reactive group selected from the group consisting of thiol, haloacetyl, pyridyl disulfide, epoxy, maleimide, hydroxyl, silanol, carboxyl, saccharide moieties and mixtures thereof, even more preferably the solid support comprises a reactive group selected from the group consisting of thiol, haloacetyl, pyridyl disulfide, maleimide and mixtures thereof.
  • the solid support comprises an affinity tag or a binding moiety for immobilization of a template or one or more enzymes used in RNA processing steps (e.g. a capping enzyme, RNA polymerase, restriction enzyme, 2'-O-methyltransferase, poly(A) polymerase, pyrophosphatase etc.).
  • the solid support may comprise a streptavidin tag to immobilize a biotinylated target such as a biotinylated DNA template or enzyme.
  • the particles with immobilized template nucleic acid and/or enzymes are subjected to manual workflows, i.e. the particles and solutions are manipulated by the user.
  • the particles with immobilized nucleic acid template and/or enzymes are subjected to automated workflows, using dedicated devices.
  • magnetic particles are used as solid support automation may include providing a device capable of magnetic separation. Examples of such devices are provided in WO2022081519 Al and W02020002598 Al.
  • the concentration of the linear DNA template in the reaction mixture of the method of the invention is in a range from about 1 to 100 nM, 1 to 50 nM, 1 to 30 nM, 1 to 20 nM, or about 1 to 10 nM. Even more preferred the concentration of the DNA template is from about 10 to 30 nM. Most preferred the concentration of the DNA template is about 20 nM.
  • the concentration of the DNA template in the final reaction mixture of the method of the invention is between 1 ng/ml to 100 pg/ml, preferably between 1 pg/ml to 3 pg/ml, most preferably 2.5 pg/ml.
  • the nucleic acid template comprising the target sequence to be transcribed, an RNA polymerase promoter site operably linked upstream to the target sequence, an RNA polymerase capable of binding the promoter site, a transcription buffer, rNTPs, a dinucleotide cap analog according to Formula I, a 2'0-methyltransferase and S-adenosylmethionine are combined in a single vessel, in order to yield the final reaction mixture based on which IVT, co-transcriptional capping and methylation of the capped mRNA is performed.
  • RNA polymerase capable of binding the promoter site
  • the RNA polymerase may be any DNA-dependent RNA polymerase capable of binding to the promoter sequence within the linearized nucleic acid template.
  • the RNA polymerase recognizes and specifically binds to the target sequence at the promoter site from where the RNA synthesis is initiated.
  • the RNA polymerase is a bacteriophage-derived RNA polymerase, preferably selected from the group comprising T7, T3, Vsw-3, Kll, T3D, T5, T8, (02.5, (06, and SP6 RNA polymerases, their variants, chimeras or mutants thereof.
  • RNA polymerase is selected from the group consisting of a T7 RNA polymerase, a T3 RNA polymerase, and a SP6 RNA polymerase.
  • RNA polymerases may be modified by exchanging, inserting or deleting amino acids of the RNA polymerase sequence. Variants may be obtained by evolving an RNA polymerase, optimizing the RNA polymerase amino acid and/or nucleic acid sequence and/or by using other methods known in the art.
  • the RNA polymerase is a T7 RNA polymerase.
  • engineered variants of RNA polymerases may be used such as thermostable variants disclosed in W02010016621 Al, US11072808 B2, WO2017123748 Al or WO2018236617 Al.
  • An RNA polymerase may also be evolved for selective incorporation of the capped GTP analogue over GTP as disclosed in W02019005539 Al or W02019005540 Al.
  • RNA polymerase may be a chimeric enzyme as disclosed in US11072808 or evolved to have improved properties, such as increased thermostability, increased transcription efficiency, 3' homogeneity, run-on transcripts, double-stranded contaminants, as disclosed in WO2019/199807, US11066686, CN112831484 or US11485960.
  • T7 RNA polymerase may comprise at least one mutation such as, but not limited to, Ml, I4M, A7T, N9, DIO, G47, E63V, V64D, A65E, D66Y, T75, T76N, A83, K93T, E108, 1109, A113, 1117, C125R, S128R, V134, A136, V137, D147, N165S, E167, K172, R173, G175R, H176L, Y178H, K179, K180, F182L, L196F, G198V, H205, K206, D208Y, E222K, V227, S228A, H230, Q239R, T243N, G259D, P266, M267I, G280C, 1281, R291, V297, H300R, Y312, 1320, A323, A327, K333, W344, V340, C347, E350, D351, A35
  • the RNA polymerase is a T3 RNA polymerase. In yet another embodiment, the RNA polymerase is an SP6 RNA polymerase. Preferably, the RNA polymerase is a T7 RNA polymerase. In addition, in an embodiment the RNA polymerase is a variant of the T7, T3 or SP6 RNA polymerase. In another embodiment, the RNA polymerase is derived from E. coli. In one embodiment, the RNA polymerase is a single subunit RNA polymerase of viral origin. In an embodiment, the RNA polymerase is derived from recombinant source. In one embodiment the RNA polymerase may be a chimeric enzyme and may be fused to another entity (such as a linker, domain, subunit of another enzyme, a tag etc.).
  • the nucleic acid template comprises a target sequence to be transcribed and an RNA polymerase promoter site operably linked upstream to the target sequence, wherein the RNA polymerase promoter is a T7 RNA polymerase promoter and the RNA polymerase used is a T7 RNA polymerase.
  • the nucleic acid template comprises a target sequence to be transcribed and an RNA polymerase promoter site operably linked upstream to the target sequence, wherein the RNA polymerase promoter is a T3 RNA polymerase promoter and the RNA polymerase used is a T3 RNA polymerase.
  • the nucleic acid template comprises a target sequence to be transcribed and an RNA polymerase promoter site operably linked upstream to the target sequence, wherein the RNA polymerase promoter is an SP6 RNA polymerase promoter and the RNA polymerase used is an SP6 RNA polymerase.
  • the invention relates to a method of synthesizing capped mRNA, comprising combining, in a single vessel: a nucleic acid template comprising a target sequence to be transcribed and a T7 RNA polymerase promoter site operably linked upstream to the target sequence, a T7 RNA polymerase or functional variant thereof, a transcription buffer, ribonucleoside triphosphates (NTPs), a dinucleotide cap analog according to Formula I, wherein R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl; R 2 is H, OH or O-CH3; R 3 is H, OH or O-CH3; R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se; R 7 and R 8 are OH; n is 1, 2, or 3; and
  • SAM S-adenosyl methionine
  • the invention relates to a method of synthesizing capped mRNA, comprising combining, in a single vessel: a nucleic acid template comprising a target sequence to be transcribed and a T3 RNA polymerase promoter site operably linked upstream to the target sequence, a T3 RNA polymerase or functional variant thereof, a transcription buffer, ribonucleoside triphosphates (NTPs), a dinucleotide cap analog according to Formula I, wherein R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl; R 2 is H, OH or O-CH3; R 3 is H, OH or O-CH3; R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se; R 7 and R 8 are OH; n is 1, 2, or 3; and
  • SAM S-adenosyl methionine
  • IVT in vitro transcription
  • the invention relates to a method of synthesizing capped mRNA, comprising combining, in a single vessel: a nucleic acid template comprising a target sequence to be transcribed and a SP6 RNA polymerase promoter site operably linked upstream to the target sequence, a SP6 RNA polymerase or functional variant thereof, a transcription buffer, ribonucleoside triphosphates (NTPs), a dinucleotide cap analog according to Formula I, wherein R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl; R 2 is H, OH or O-CH3; R 3 is H, OH or O-CH3; R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se; R 7 and R 8 are OH; n is 1, 2, or 3; and
  • SAM S-adenosyl methionine
  • the concentration of the RNA polymerase in the final reaction mixture is from about 1 to 100 nM, 1 to 90 nM, 1 to 80 nM, 1 to 70 nM, 1 to 60 nM, 1 to 50 nM, 1 to 40 nM, 1 to 30 nM, 1 to 20 nM, or about 1 to 10 nM. Even more preferred, the concentration of the RNA polymerase is from about 10 to 100 nM, about 10 to 80 nM, about 20 to 70 nM, or 50 to 70 nM. Most preferably, the RNA polymerase has a final concentration of 60 nM
  • RNA polymerase concentration in the final reaction mixture is about 60 nM.
  • concentration of the RNA polymerase in the final reaction mixture is between 1 and 1000 U/pg template DNA, preferably between 100 and 300 U/pg DNA, particularly if plasmid DNA is used as template DNA.
  • the transcription buffer comprises a buffering agent, magnesium, reducing agents such as dithiothreitol (DTT) and/or additional components.
  • the transcription buffer comprises magnesium ions, dithiothreitol (DTT) and polyamine additives.
  • polyamine is spermidine.
  • the transcription buffer comprises detergent.
  • Common buffer systems or buffering agents used in RNA in vitro transcription include 4-(2-hydroxy- ethyl)-l-piperazineethanesulfonic acid (HEPES) and tris(hydroxymethyl)amino- methane (Tris), other non-limiting examples include TAPS (tris(hydroxymethyl)methylamino]propanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), tricine, or MES (2-Morpholinoethanesulphonic acid).
  • the pH of the buffer is commonly adjusted to a pH value of 6 to 9.
  • a reaction buffer has a pH of 7-9.
  • the transcription buffer comprises magnesium salt and/or other salts, a buffering agent, reducing agent, and/or other ingredients.
  • other salts are ammonium sulfate, sodium bicarbonate, sodium citrate, sodium acetate, potassium phosphate, sodium phosphate and/or sodium chloride.
  • the transcription buffer comprises magnesium (Mg 2+ ; e.g., a magnesium salt), preferably MgCL.
  • magnesium salt is magnesium acetate.
  • the concentration of magnesium present in the final reaction can be, for example, 1-60 mM, preferably 2-50 mM, more preferably 5-40 mM, even more preferably 10-30 mM.
  • the final reaction composition comprises magnesium at a concentration of 10 mM.
  • the final reaction mixture comprises MgCL at a concentration of 15 mM.
  • the final reaction mixture comprises MgCL at a concentration of 20 mM.
  • the final reaction mixture comprises MgCL at a concentration of 25 mM.
  • the final reaction mixture comprises MgCL at a concentration of 30 mM. In a specific embodiment, the final reaction mixture comprises magnesium at 12 mM. In a specific embodiment, the final reaction mixture comprises magnesium at 8 mM. In a specific embodiment, the final reaction mixture comprises magnesium at 6 mM.
  • the molar ratio of rNTP to magnesium ions (Mg 2+ ; e.g., MgCL) present in the IVT reaction is from 1:1 to 1:5.
  • the molar ratio of NTP to magnesium ion in the final reaction may be 1:1, 1:2, 1:3, 1:4 or 1:5.
  • the transcription buffer comprises a reducing agent.
  • a reducing agent comprises dithithreitol (DTT) and/or 2 -mercaptoethanol.
  • the reducing agent is DTT.
  • the concentration of DTT present in the final reaction can be, for example, at least 1 mM, at least 5 mM, or at least 10 mM, or 1-50 mM, preferably 1-30 mM, more preferably 5- 10 mM, even more preferably 7-15 mM.
  • the final reaction mixture comprises DTT at a concentration of 10 mM.
  • the final reaction mixture comprises DTT at a concentration of 5 mM.
  • the transcription buffer comprises spermidine.
  • concentration of spermidine present in the final reaction can be, for example, 0.1-10 mM, preferably 0.1-5 mM, more preferably 0.5-4 mM, even more preferably 2-5 mM.
  • the final reaction mixture comprises spermidine at a concentration of 2 mM.
  • the final reaction mixture comprises spermidine at a concentration of 1 mM.
  • the transcription buffer comprises a detergent.
  • the detergent includes Triton X-100, sodium dodecyl sulfate (SDS), CHAPS (3-[(3- cholamidopropyl)dirnethylammonio]-l-propanesulfonate), ethyl trimethyl ammonium bromide, nonyl phenoxypolyethoxylethanol (NP-40), Poloxamer 188 and/or polyethylene glycol (PEG).
  • the transcription buffer comprises Tris as a buffering agent.
  • the concentration of Tris used in the final reaction can be, for example, at least 10 mM, at least 20 mM, at least 30 mM, at least 40 mM, at least 50 mM, at least 60 mM, at least 70 mM, at least 80 mM, at least 90 mM, at least 100 mM or at least 110 mM.
  • the final concentration of Tris in the final reaction is 40 mM.
  • the final concentration of Tris in the final reaction is 50 mM.
  • the transcription buffer optionally further comprises additional components.
  • additional component is NaCI.
  • NaCI concentration in the final reaction is from 5 mM to 50 mM. In some embodiments NaCI concentration in the final reaction is 10 mM. In some embodiments NaCI concentration in the final reaction is 20 mM.
  • transcription buffer composition could be: 40 mM Tris-HCI, 27.5 mM MgCL, 10 mM DTT, 2 mM spermidine. In a different embodiment, transcription buffer composition is: 40 mM Tris-HCI, 6 mM MgCL, 20 mM NaCI, 10 mM DTT, 2 mM spermidine. In another embodiment, transcription buffer composition is: 40 mM Tris-HCI, 8 mM MgCL, 25 mM NaCI, 2 mM spermidine. In another embodiment, transcription buffer composition is: 40 mM Tris-HCI, 6 mM MgCL, 10 mM DTT, 2 mM spermidine.
  • transcription buffer composition is: 40 mM Tris-HCI, 6 mM MgCL, 10 mM NaCI, 2 mM spermidine. In another embodiment, transcription buffer composition is: 40 mM Tris-HCI, 6 mM MgCL, 10 mM DTT, 2 mM spermidine. In another embodiment, transcription buffer composition is: 40 mM Tris-HCI, 46 mM MgCL, 10 mM DTT, 2 mM spermidine. In another embodiment, transcription buffer composition is: 40 mM Tris-HCI, 6 mM MgCL, 10 mM DTT, 2 mM spermidine.
  • transcription buffer composition is: 40 mM Tris-HCI, 80 mM MgCL, 50 mM mM NaCI, 10 mM DTT, 2 mM spermidine. In another embodiment, transcription buffer composition is: 40 mM Tris-HCI, 12 mM MgCL, 10 mM DTT, 2 mM spermidine.
  • the ribonucleoside triphosphates comprise ATP, CTP, UTP, GTP and any modified ribonucleotide.
  • the modification may be one or more of a backbone modification, a sugar modification and/or a nucleobase modification.
  • a backbone modification is a modification, in which phosphates of the backbone of the ribonucleotides are chemically modified.
  • a sugar modification in connection with the present invention is a chemical modification of the sugar of the ribonucleotides.
  • a base modification in connection with the present invention is a chemical modification of the base moiety of the ribonucleotides.
  • ribonucleotide modifications are applicable for transcription and/or translation
  • a part or all of at least one ribonucleoside triphosphate in the reaction mixture is replaced with a modified nucleoside triphosphate.
  • the ribonucleoside triphosphates provided herein include unmodified or modified ATP, modified or unmodified UTP, modified or unmodified GTP, and/or modified or unmodified CTP.
  • the rNTPs of in the reaction mixture comprise unmodified ATP.
  • the rNTPs of in the reaction mixture comprise modified ATP.
  • the rNTPs of in the reaction mixture comprise an unmodified UTP.
  • the rNTPs of in the reaction mixture comprise a modified UTP.
  • said modified nucleoside triphosphate is selected from the group consisting of pseudouridine-5'-triphosphate, l-methylpseudouridine-5'-triphosphate, 2- thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate and 5-methylcytidine-5'-triphosphate.
  • a part or all of UTP in the reaction mixture is replaced with a modified UTP selected from the group consisting of pseudouridine-5'-triphosphate, 1- methylpseudouridine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate.
  • a part or all of CTP in the reaction mixture is replaced with 5-methylcytidine-5'-triphosphate.
  • nucleotides for base modifications selected from the group of base-modified nucleotides consisting of 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine- 5'-triphosphate, and pseudouridine-5'-triphosphate.
  • Modified ribonucleosides may be selected from pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5- aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3- methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1- propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl- 2-thio-uridine, l-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-l- methyl-pseudouridine, 2-thio-l-methyl-pseudouridine, 1-methyl-l-deaza-pseu
  • Modified ribonucleosides may be selected from 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl- pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl- cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio-l-methyl-l-deaza- pseudoisocytidine, 1-methyl-l-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl- zebularine, 5-aza-2-thio-zebularine, 2-thio-zebul
  • Modified ribonucleosides may be selected from 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6- diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6- isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis- hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6
  • Modified ribonucleosides may be selected from inosine, 1-methyl-inosine, wyosine, wybutosine, 7- deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7- deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6- methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo- guanosine, 7-methyl-8-oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, a-thio-guanosine, 6-methyl-gua
  • the ribonucleotide can be modified on the major groove face and can include replacing hydrogen on C-5 of uracil with a methyl group or a halo group.
  • the single ribonucleotides ATP, GTP, CTP, UTP, and any modified ATP, GTP, CTP, UTP are provided in a concentration between 0.1 and 20 mM, preferably between 1 and 10, preferably between 3 and 7 mM, more preferably between 4 mM and 6 mM, and most preferably in a concentration of 5 mM.
  • GTP is present in a ratio GTP:dinucleotide cap analog from 1:1 to 1:10.
  • GTP is present in a ratio GTP:dinucleotide cap analog from 1:1 to 1:8, from 1:1 to 1:7, from 1:1 to 1:6, from 1:1 to 1:5, from 1:1 to 1:4, from 1:1 to 1:3, from 1:1 to 1:2.
  • GTP is present in a ratio GTP:dinucleotide cap analog from 1:3 to 1:5.
  • GTP is present in a ratio GTP:dinucleotide cap analog of 1:4.
  • the single ribonucleotide GTP and any modified GTP is provided in a concentration between 0.1 and 10 mM, preferably between 0.1 and 5 mM, more preferably between 0.5 mM and 2 mM, and most preferably in a concentration of 1 mM.
  • the dinucleotide cap analog is a compound of Formula I: wherein
  • R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cs heterocyclyl, C 5 -Cs substituted heterocyclyl;
  • R 2 is H, OH or O-CH 3 ;
  • R 3 is H, OH or O-CH 3 ;
  • R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se;
  • R 7 and R 8 are OH; n is 1, 2, or 3; and
  • B is a non-modified or modified purine or pyrimidine base.
  • a noteddinucleotide cap analog is a dinucleotide consisting of an outer cap nucleoside, such as 7-methyl- guanosine (m7G), and the nucleotide corresponding to the first nucleotide of the primary transcript (e.g., G) depicted as "B" in Formula I. Therefore, an exemplary cap analog is the m7G(5')ppp(5')G, also referred to as m 7 GpppG. This cap analog is often used because the primary nucleotide (i.e., the most 5' nucleotide) of most, but not all, primary RNA transcripts synthesized using phage RNA polymerase transcription systems is guanosine.
  • m7G 7-methyl- guanosine
  • the dinucleotide cap analogs are enzymatically incorporated at the mRNA 5'-end by the RNA polymerase, e.g., bacteriophage T7 RNA polymerase during in vitro transcription reaction, i.e., co- transcriptionally.
  • the RNA polymerase e.g., bacteriophage T7 RNA polymerase during in vitro transcription reaction, i.e., co- transcriptionally.
  • cap analogue is m 7 GpppG but several modified or alternative cap analogues are also accepted by RNA polymerases. Therefore, this route can also be used to install non-natural dinucleotides at the 5'-end that are accessible for a further chemical reaction.
  • the dinucleotide cap analog is an anti-reverse cap analog (ARCA).
  • the dinucleotide cap analog is methylated at the 2' -OH or at the 3'-OH of the N 7 -methylguanosine ribose (m2 7,3 O GpppN or m2 7,2 O GpppN). This prevents elongation at the "wrong" 3'-OH and thus prevents yielding mRNA with the cap in reverse orientation as ARCA caps are exclusively incorporated in the correct orientation.
  • the dinucleotide cap analog has Formula I, wherein one of R 2 or R 3 of the dinucleotide cap analog is O-CH3. In a preferable embodiment, the dinucleotide has Formula I, wherein R 2 is OH and R 3 is O-CH3. In another preferable embodiment, the dinucleotide has Formula I, wherein R 2 is O-CH3 and R 3 is OH.
  • the dinucleotide cap analog may preferably have a 3'-O-methyl ribose modification or a 2'-O-methyl ribose modification and may have three, four or five phosphate moieties, i.e., m2 7,3 O GpppN or rr ⁇ 7,2 - °GpppN, m2 7,3 O GppppN or m2 7,2 O GppppN, m2 7,3 O GpppppN or m2 7,2 O GpppppN.
  • B (N) is guanosine
  • the dinucleotide cap analog is an anti-reverse cap analog (ARCA) having the structural formula of m2 7,3 O GpppG also abbreviated as 3'-O-Me-m 7 G(5')pppG(5'):
  • ARCA anti-reverse cap analog
  • the concentration of the dinucleotide cap analog in the reaction mixture is between 0.1 and 100 mM, between 1 and 50 mM, preferably between 1 and 10 mM, and most preferably between 3 and 5 mM.
  • the dinucleotide cap analog is present in the reaction mixture at a concentration of 4 mM.
  • the dinucleotide cap analog is present in the reaction mixture at a concentration of 5 mM.
  • the total rNTP concentration in the reaction mixture is between 1 and 100 mM, preferably between 10 and 50 mM, and most preferably between 15 and 25 mM.
  • the term total ribonucleotide concentration means the total concentration of rNTPs, e.g. the sum of the concentrations of ATP, GTP, CTP, UTP, optionally any modified rNTP and the dinucleotide cap present initially in the reaction when the various components of the reaction have been assembled in the final volume for carrying out the reaction.
  • the nucleotides will be incorporated into the RNA molecule and consequently the total nucleotide concentration will be progressively reduced from its initial value.
  • the concentrations of dinucleotide cap analogs and nucleoside triphosphates present in the IVT reaction can vary, as described for the rNPTs before.
  • the NTP and dinucleotide cap analogs are present in equimolar concentrations in the reaction. That means the molar ratio of dinucleotide cap analog to rNTP is 1:1.
  • the molar ratio of the dinucleotide cap analog to nucleoside triphosphate in the reaction is greater than 1:1.
  • the molar ratio of cap analog to nucleoside triphosphate in the reaction is 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1.
  • the molar ratio of the dinucleotide cap analog to nucleoside triphosphate in the reaction is less than 1:1. In some embodiments, the molar ratio of the dinucleotide cap analog to nucleoside triphosphate in the reaction is less than 4:5. In an embodiment, the molar ratio of the dinucleotide cap analog to nucleoside triphosphate ranges from 1:1 to 8:1. In an embodiment, the molar ratio of the dinucleotide cap analog to nucleoside triphosphate ranges from 0.2:1 to 8:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to ATP is 1:1.
  • the molar ratio of the dinucleotide cap analog to CTP is 1:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to UTP is 1:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to a modified ATP, CTP or UTP is 1:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to GTP ranges from 1:1 to 8:1. In a specific embodiment, the dinucleotide cap analog is present at a ratio dinucleotide cap analog to GTP of 4:1.
  • Cap-0 transcripts can be enzymatically converted to cap-1 in vitro.
  • mRNA cap 2'-0-methyltransferase adds a methyl group at the 2'-0 position of the first nucleotide adjacent to the cap structure at the 5' end of the RNA.
  • the enzyme utilizes S-adenosylmethionine (SAM) as a methyl donor to methylate capped RNA (Cap-0) resulting in a Cap-1 structure. It has been reported that such capl structure may result in a higher translational-competency (Kuge et al. (1998) Nucl. Acids Res. 26(13): 3208-3214.) and cellular stability and a reduced activation of cellular pro- inflammatory cytokines, as compared, e.g., to other cap analog structures known in the art.
  • SAM S-adenosylmethionine
  • the 2'-O-methyltransferase is of viral origin. In preferable embodiments, the 2'-O- methyltransferase is derived from a Vaccinia virus. In embodiments, the 2'-O-methyltransferase is a Vaccinia virus cap-specific ribonucleoside 2'-O-methyltransferase, functional mutant, chimera or variant thereof. In an embodiment, 2'-O-methyltransferase is derived from SARS-CoV-2.
  • the 2'-O-methyltransferase is RNA polymerase exhibiting 2'-O-methyltransferase activity (see for example "An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization", Egloff et al., 2002, The EMBO Journal.)
  • the 2'-O-methyltransferase transfers a methyl group from the co-substrate SAM to the target molecule.
  • concentration of 2'O-methyltransferase in the final reaction is between 10 and 100 Units.
  • concentration of 2'-O-methyltransferase in the final reaction is between 25 and 75 Units.
  • concentration of 2'-O-methyltransferase in the final reaction is about 50 Units.
  • concentration of 2'-O-methyltransferase in the final reaction is 50 Units.
  • SAM S-adenosylmethionine
  • S-adenosylmethionine As used herein, "S-adenosylmethionine”, “S-Adenosyl-L-methionine”, “SAM”, and “AdoMet” are used interchangeably and refer to a compound having formula C15H22N6O5.
  • the 2'-O-methyltransferase transfers a methyl group from the co-substrate S-adenosyl-L-methionine to first nucleotide adjacent to the cap structure at the 5' end of the mRNA.
  • the concentration of S-adenosylmethionine in the final reaction is between 0.05 and 1 mM.
  • the concentration of S-adenosylmethionine in the final reaction is 0.2-0.3 mM.
  • the concentration of S-adenosylmethionine in the final reaction is about 0.25 mM. In preferred embodiments, the concentration of S-adenosylmethionine in the final reaction is 0.25 mM.
  • the composition optionally further comprises a poly(A) polymerase.
  • a poly(A) tail may also be added post transcriptionally by enzymatic polyadenylation using a poly(A) polymerase.
  • Poly(A) polymerase catalyzes the templateindependent addition of AMP from ATP to the 3' end of RNA.
  • the poly(A) polymerase may be modified or unmodified.
  • the modified or unmodified poly(A) polymerase is of bacterial origin.
  • the modified or unmodified poly(A) polymerase is derived from Escherichia coli.
  • the method of the invention is performed under conditions allowing for co-transcriptional mRNA capping and methylation of capped mRNA within the same reaction.
  • the in vitro transcription of the DNA template, the capping of the transcribed mRNA and the 2'0-methylation of the first ribonucleotide of the transcribed mRNA is all performed within one single reaction.
  • Thais means, IVT, co-transcriptional capping and methylation of capped mRNA is performed simultaneously. Therefore, methylation of the capped mRNA is performed without prior mRNA purification.
  • the present invention provides a method of performing an IVT reaction, comprising contacting a DNA template with the RNA polymerase in the presence of nucleoside triphosphates, a dinucleotide cap analog and buffer under conditions that result in the production of capped mRNA.
  • the presence of the 2'-O-methyltransferase and SAM within the IVT reaction mixture allows for methylation of the first nucleotide of the mRNA next to the cap structure within the same reaction.
  • the disclosed method is an in vitro method.
  • In vitro transcription may also be performed in a living system, of the IVT components are delivered to a cell.
  • the inventive method disclosed herein results in more than 95% of the RNA transcripts produced comprising a functional cap-1 structure.
  • greater than 96% of the RNA transcripts produced comprise a functional cap-1 structure.
  • greater than 97% of the RNA transcripts produced comprise a functional cap-1 structure.
  • greater than 98% of the RNA transcripts produced comprise a functional cap-1 structure.
  • greater than 99% of the RNA transcripts produced comprise a functional cap-1 structure.
  • 100% of the RNA transcripts produced comprise a functional cap-1 structure.
  • methylation of capped mRNA is performed without prior mRNA purification.
  • RNA transcripts produced by the present method can be used to produce polypeptides of interest, e.g., therapeutic proteins, vaccine antigens, and the like.
  • the RNA transcript is a therapeutic RNA.
  • a therapeutic mRNA is an mRNA encoding a therapeutic protein (the term 'protein 1 encompasses peptides).
  • Therapeutic proteins mediate various effects in a host cell or in a subject to treat a disease or ameliorate the signs and symptoms of a disease.
  • a therapeutic protein can replace a deficient or abnormal protein, enhance the function of an endogenous protein, or provide a new function to the cell (e.g., inhibit or activate endogenous cellular activity), or can serve as a delivery agent for another therapeutic compound (e.g., antibodydrug conjugate).
  • Therapeutic mRNA can be used, for example, for the following diseases and conditions: bacterial infection, viral infection, parasitic infection, cell proliferation. It can be useful in the treatment of disorders, genetic disorders, and autoimmune disorders. Other diseases and conditions are encompassed herein.
  • a protein of interest encoded by an mRNA when provided herein can be essentially any protein.
  • the invention provides for a composition for use in the synthesis of capl-type mRNA from a nucleic acid template.
  • the composition comprises an RNA polymerase, a transcription buffer, ribonucleoside triphosphates (rNTPs), a dinucleotide cap analog according to Formula I, a 2'0- methyltransferase and S-adenosylmethionine.
  • the composition comprising all ingredients is provided in only one vessel.
  • the RNA polymerase is capable of binding a promoter site operably linked upstream to a target sequence comprised on a nucleic acid template.
  • the dinucleotide cap analog comprised in the composition is a dinucleotide cap analog according to Formula I wherein
  • R 1 is selected from methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, C 5 -Cg heterocyclyl, C 5 -Cg substituted heterocyclyl;
  • R 2 is H, OH or O-CH 3 ;
  • R 3 is H, OH or O-CH 3 ;
  • R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se;
  • R 7 and R 8 are OH; n is 1, 2, or 3; and B is a non-modified or modified purine or pyrimidine base.
  • RNA polymerase capable of binding the promoter site
  • the RNA polymerase may be any DNA-dependent RNA polymerase capable of binding to the promoter sequence within the linearized nucleic acid template.
  • the RNA polymerase recognizes and specifically binds to the target sequence at the promoter site from where the RNA synthesis is initiated.
  • the RNA polymerase is a bacteriophage-derived RNA polymerase, preferably selected from the group comprising T7, T3, Vsw-3, Kll, T3D, T5, T8, (02.5, (06, and SP6 RNA polymerases, their variants, chimeras or mutants thereof.
  • RNA polymerase is selected from the group consisting of a T7 RNA polymerase, a T3 RNA polymerase, and a SP6 RNA polymerase.
  • RNA polymerases may be modified by exchanging, inserting or deleting amino acids of the RNA polymerase sequence. Variants may be obtained by evolving an RNA polymerase, optimizing the RNA polymerase amino acid and/or nucleic acid sequence and/or by using other methods known in the art.
  • the RNA polymerase is a T7 RNA polymerase.
  • engineered variants of RNA polymerases may be used such as thermostable variants disclosed in W02010016621 Al, US11072808 B2, WO2017123748 Al or WO2018236617 Al.
  • An RNA polymerase may also be evolved for selective incorporation of the capped GTP analogue over GTP as disclosed in W02019005539 Al or W02019005540 Al.
  • RNA polymerase may be a chimeric enzyme as disclosed in US11072808 or evolved to have improved properties, such as increased thermostability, increased transcription efficiency, 3' homogeneity, run-on transcripts, double-stranded contaminants, as disclosed in WO2019/199807, US11066686, CN112831484 or US11485960.
  • T7 RNA polymerase may comprise at least one mutation such as, but not limited to, Ml, I4M, A7T, N9, DIO, G47, E63V, V64D, A65E, D66Y, T75, T76N, A83, K93T, E108, 1109, A113, 1117, C125R, S128R, V134, A136, V137, D147, N165S, E167, K172, R173, G175R, H176L, Y178H, K179, K180, F182L, L196F, G198V, H205, K206, D208Y, E222K, V227, S228A, H230, Q239R, T243N, G259D, P266, M267I, G280C, 1281, R291, V297, H300R, Y312, 1320, A323, A327, K333, W344, V340, C347, E350, D351, A35
  • the RNA polymerase is a T3 RNA polymerase. In yet another embodiment, the RNA polymerase is an SP6 RNA polymerase. Preferably, the RNA polymerase is a T7 RNA polymerase. In addition, in an embodiment the RNA polymerase is a variant of the T7, T3 or SP6 RNA polymerase. In another embodiment, the RNA polymerase is derived from E. coli. In one embodiment, the RNA polymerase is a single subunit RNA polymerase of viral origin. In an embodiment, the RNA polymerase is derived from recombinant source. In one embodiment the RNA polymerase may be a chimeric enzyme and may be fused to another entity (such as a linker, domain, subunit of another enzyme, a tag etc.).
  • the composition disclosed herein can be used for the synthesis of mRNA in a bioreactor.
  • the composition is used for a transcription reaction carried out in a transcription reactor (bioreactor).
  • the bioreactor is configured such that reactants are delivered via a feed line to the reactor core and RNA products are removed by passing through an ultrafiltration membrane (having a nominal molecular weight cut-off, e.g., 100,000 daltons) to the exit stream.
  • the ultrafiltration membrane may be composed of a low protein-binding polymer matrix and serves to selectively retain both the RNA polymerase and the immobilized DNA templates in the reactor core.
  • the transcription reactor is operated in either semi-batch or continuous-flow modes.
  • bioreactors are set up to produce either short RNA species (from approximately twenty to approximately one hundred nucleotides in length) or RNA species greater than one hundred nucleotides in length.
  • bioreactor operates in a continuous mode, and is configured for continuous synthesis of an RNA molecule by in vitro transcription using reactants disclosed herein.
  • the apparatus comprises a reaction module, a control module, and a mRNA separation.
  • the reaction module, the control module, and the mRNA separation system are in operable communication with one another.
  • the bioreactor includes at least one inlet connected to a supply line that feeds (supplies) the reactants for the reaction to the bioreactor.
  • the apparatus includes a plurality of supply lines each of which independently supplies a reactant for the reaction to the bioreactor.
  • the bioreactor includes an outlet from which the reaction product is transported to the mRNA separation system.
  • the control module comprises at least one sensor and provides feedback control of the reaction mixture in the reaction module as well as feedback control of the reaction product in the RNA separation system.
  • the control module receives and analyzes data received from the at least one sensor.
  • the sensor comprises a plurality of sensors that independently monitor nucleotide triphosphates, capping molecules, RNA polymerase, buffer, magnesium levels, or a combination thereof in the reaction mixture. When the concentration of the reactant falls below the threshold level, the reactant is supplied to the bioreactor.
  • the concentration of the reactant falls below the threshold level, the reactant is supplied to the bioreactor.
  • composition disclosed herein can be used in an automated apparatus, device or platform for RNA production.
  • automated RNA synthesis device can be an RNA printerTM.
  • the composition disclosed herein can be used for the synthesis of mRNA in a continuous flow device or a flow reactor.
  • the flow device may be a liquid flow device.
  • a flow device may comprise one or more bioreactors.
  • the flow device may be a continuous flow device.
  • the flow reactor may be a liquid flow reactor.
  • the flow reactor may be a continuous flow reactor.
  • the concentration of the RNA polymerase in the final reaction mixture is from about 1 to 100 nM, 1 to 90 nM, 1 to 80 nM, 1 to 70 nM, 1 to 60 nM, 1 to 50 nM, 1 to 40 nM, 1 to 30 nM, 1 to 20 nM, or about 1 to 10 nM. Even more preferred, the concentration of the RNA polymerase is from about 10 to 100 nM, about 10 to 80 nM, about 20 to 70 nM, or 50 to 70 nM. Most preferably, the RNA polymerase has a final concentration of 60 nM
  • RNA polymerase concentration in the final reaction mixture is about 60 nM.
  • concentration of the RNA polymerase in the final reaction mixture is between 1 and 1000 U/pg template DNA, preferably between 100 and 300 U/pg DNA, particularly if plasmid DNA is used as template DNA.
  • Common buffer systems used in RNA in vitro transcription include 4-(2-hydroxy- ethyl)- 1- piperazineethanesulfonic acid (HEPES) and tris(hydroxymethyl)amino- methane (Tris).
  • HEPES 4-(2-hydroxy- ethyl)- 1- piperazineethanesulfonic acid
  • Tris tris(hydroxymethyl)amino- methane
  • the pH value of the buffer is commonly adjusted to a pH value of 6 to 8.5.
  • the transcription buffer comprises a buffering agent, magnesium, dithiothreitol (DTT) and/or additional components.
  • the transcription buffer comprises magnesium ions, dithiothreitol (DTT) and polyamine additives.
  • polyamine is spermidine.
  • the transcription buffer comprises detergents.
  • the transcription buffer comprises magnesium salt and/or other salts, a buffering agent, DTT, and/or other ingredients.
  • the buffering agent may be Tris, TES, Tricine, TAPS, and/or HEPPS.
  • the transcription buffer comprises magnesium (Mg 2+ ; e.g., a magnesium salt), preferably MgCL.
  • the concentration of magnesium present in the final reaction can be, for example, 1-60 mM, preferably 2-50 mM, more preferably 5-40 mM, even more preferably 10-30 mM.
  • the final reaction composition comprises magnesium at a concentration of 10 mM.
  • the final reaction mixture comprises MgCL at a concentration of 15 mM.
  • the final reaction mixture comprises MgCL at a concentration of 20 mM.
  • the final reaction mixture comprises MgCL at a concentration of 25 mM.
  • the final reaction mixture comprises MgCL at a concentration of 30 mM.
  • the molar ratio of rNTP to magnesium ions (Mg 2+ ; e.g., MgCL) present in the IVT reaction is from 1:1 to 1:5.
  • the molar ratio of NTP to magnesium ion in the final reaction may be 1:1, 1:2, 1:3, 1:4 or 1:5.
  • the transcription buffer comprises DTT.
  • concentration of DTT present in the final reaction can be, for example, at least 1 mM, at least 5 mM, or at least 10 mM, or 1-50 mM, preferably 1-30 mM, more preferably 5-10 mM, even more preferably 7-15 mM.
  • the final reaction mixture comprises DTT at a concentration of 10 mM.
  • the final reaction mixture comprises DTT at a concentration of 5 mM.
  • the transcription buffer comprises spermidine.
  • concentration of spermidine present in the final reaction can be, for example, 0.1-10 mM, preferably 0.1-5 mM, more preferably 0.5-4 mM, even more preferably 2-5 mM.
  • the final reaction mixture comprises spermidine at a concentration of 2 mM.
  • the final reaction mixture comprises spermidine at a concentration of 1 mM.
  • the transcription buffer comprises Tris as a buffering agent.
  • concentration of Tris used in the final reaction can be, for example, at least 10 mM, at least 20 mM, at least 30 mM, at least 40 mM, at least 50 mM, at least 60 mM, at least 70 mM, at least 80 mM, at least 90 mM, at least 100 mM or at least 110 mM.
  • NDPs Ribonucleoside triphosphates
  • the ribonucleoside triphosphates comprise ATP, CTP, UTP, GTP and any modified ribonucleotide.
  • the modification may be one or more of a backbone modification, a sugar modification and/or a nucleobase modification.
  • a backbone modification is a modification, in which phosphates of the backbone of the ribonucleotides are chemically modified.
  • a sugar modification in connection with the present invention is a chemical modification of the sugar of the ribonucleotides.
  • a base modification in connection with the present invention is a chemical modification of the base moiety of the ribonucleotides.
  • ribonucleotide modifications are applicable for transcription and/or translation
  • a part or all of at least one ribonucleoside triphosphate in the reaction mixture is replaced with a modified nucleoside triphosphate.
  • the ribonucleoside triphosphates provided herein include unmodified or modified ATP, modified or unmodified UTP, modified or unmodified GTP, and/or modified or unmodified CTP.
  • the rNTPs of in the reaction mixture comprise unmodified ATP.
  • the rNTPs of in the reaction mixture comprise modified ATP.
  • the rNTPs of in the reaction mixture comprise an unmodified UTP.
  • the rNTPs of in the reaction mixture comprise a modified UTP.
  • the rNTPs of in the reaction mixture comprise unmodified GTP. In some embodiments, the rNTPs of in the reaction mixture comprise modified GTPs. In some embodiments, the rNTPs of in the reaction mixture comprise unmodified CTPs. In some embodiments, the rNTPs of in the reaction mixture comprise modified CTPs.
  • said modified nucleoside triphosphate is selected from the group consisting of pseudouridine-5'-triphosphate, l-methylpseudouridine-5'-triphosphate, 2- thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate and 5-methylcytidine-5'-triphosphate.
  • a part or all of UTP in the reaction mixture is replaced with a modified UTP selected from the group consisting of pseudouridine-5'-triphosphate, 1- methylpseudouridine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate.
  • a part or all of CTP in the reaction mixture is replaced with 5-methylcytidine-5'-triphosphate.
  • the ribonucleotide modifications may be selected from base modifications, which are preferably selected from 2-amino-6-chloropurineriboside-5'-triphosphate, 2-Aminopurine-riboside- 5'-triphosphate; 2-aminoadenosine-5'-triphosphate, 2'-Amino-2'-deoxycytidine-triphosphate, 2- thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 2'-Fluorothymidine-5'-triphosphate, 2'-O- Methyl inosine-5'-triphosphate 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'- triphosphate, 5-Bromo-2'-deoxycytidine-5'-triphosphate,
  • nucleotides for base modifications selected from the group of base-modified nucleotides consisting of 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine- 5'-triphosphate, and pseudouridine-5'-triphosphate.
  • Modified ribonucleosides may be selected from pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5- aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3- methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1- propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl- 2-thio-uridine, l-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-l- methyl-pseudouridine, 2-thio-l-methyl-pseudouridine, 1-methyl-l-deaza-pseu
  • Modified ribonucleosides may be selected from 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl- pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl- cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio-l-methyl-l-deaza- pseudoisocytidine, 1-methyl-l-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl- zebularine, 5-aza-2-thio-zebularine, 2-thio-zebul
  • Modified ribonucleosides may be selected from 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6- diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6- isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis- hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6
  • Modified ribonucleosides may be selected from inosine, 1-methyl-inosine, wyosine, wybutosine, 7- deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7- deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6- methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo- guanosine, 7-methyl-8-oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, a-thio-guanosine, 6-methyl-gua
  • the ribonucleotide can be modified on the major groove face and can include replacing hydrogen on C-5 of uracil with a methyl group or a halo group.
  • a modified ribonucleoside is 5'-O-(l-Thiophosphate)-Adenosine, 5'-O-(l- Thiophosphate)-Cytidine, 5'-O-(l-Thiophosphate)-Guanosine, 5'-O-(l-Thiophosphate)-Uridine or 5'- O-(1-Thiophosphate)-Pseudouridine.
  • the total rNTP concentration in the reaction mixture is between 1 and 200 mM, preferably between 2 and 100 mM, preferably between 10 and 50 mM, and most preferably between 15 and 25 mM.
  • total ribonucleotide concentration means the total concentration of rNTPs, i.e., the sum of the concentrations of ATP, GTP, CTP, UTP, optionally any modified rNTP and the dinucleotide cap analog present initially in the reaction when the various components of the reaction have been assembled in the final volume for carrying out the reaction.
  • the nucleotides will be incorporated into the RNA molecule and consequently the total nucleotide concentration will be progressively reduced from its initial value.
  • the single ribonucleotides ATP, GTP, CTP, UTP, and any modified ATP, GTP, CTP, UTP are provided in a concentration between 0.1 and 20 mM, preferably between 1 and 10, preferably between 3 and 7 mM, more preferably between 4 mM and 6 mM, and most preferably in a concentration of 5 mM.
  • GTP is present in a ratio GTP:dinucleotide cap analog from 1:1 to 1:10.
  • GTP is present in a ratio GTP:dinucleotide cap analog from 1:1 to 1:8, from 1:1 to 1:7, from 1:1 to 1:6, from 1:1 to 1:5, from 1:1 to 1:4, from 1:1 to 1:3, from 1:1 to 1:2.
  • GTP is present in a ratio GTP:dinucleotide cap analog from 1:3 to 1:5.
  • GTP is present in a ratio GTP:dinucleotide cap analog of 1:4.
  • the single ribonucleotide GTP and any modified GTP is provided in a concentration between 0.1 and 10 mM, preferably between 0.1 and 5 mM, more preferably between 0,5 mM and 2 mM, and most preferably in a concentration of 1 mM.
  • the dinucleotide cap analog is a compound of Formula I: wherein
  • R 3 is H, OH or O-CH 3 ;
  • R 4 , R 5 and R 6 are independently selected from the group consisting of O, S, Se;
  • R 7 and R 8 are OH; n is 1, 2, or 3; and
  • B is a non-modified or modified purine or pyrimidine base.
  • a noteddinucleotide cap analog is a dinucleotide consisting of an outer cap nucleoside, such as 7-methyl- guanosine (m7G), and the nucleotide corresponding to the first nucleotide of the primary transcript (e.g., G) depicted as "B" in Formula I. Therefore, an exemplary cap analog is the m7G(5')ppp(5')G, also referred to as m 7 GpppG. This cap analog is often used because the primary nucleotide (i.e., the most 5' nucleotide) of most, but not all, primary RNA transcripts synthesized using phage RNA polymerase transcription systems is guanosine.
  • m7G 7-methyl- guanosine
  • the dinucleotide cap analogs are enzymatically incorporated at the mRNA 5'-end by the RNA polymerase, e.g., bacteriophage T7 RNA polymerase during in vitro transcription reaction, i.e., co- transctiptionally.
  • the RNA polymerase e.g., bacteriophage T7 RNA polymerase during in vitro transcription reaction, i.e., co- transctiptionally.
  • cap analogue is m 7 GpppG but several modified or alternative cap analogues are also accepted by RNA polymerases. Therefore, this route can also be used to install non-natural dinucleotides at the 5'-end that are accessible for a further chemical reaction.
  • the dinucleotide cap analog is an anti-reverse cap analog (ARCA).
  • the dinucleotide cap analog is methylated at the 2' -OH or at the 3'-OH of the N 7 -methylguanosine ribose (m2 7,3 O GpppN or m2 7,2 O GpppN). This prevents elongation at the "wrong" 3'-OH and thus prevents yielding mRNA with the cap in reverse orientation as ARCA caps are exclusively incorporated in the correct orientation.
  • the dinucleotide cap analog has Formula I, wherein one of R 2 or R 3 of the dinucleotide cap analog is O-CH 3 .
  • the dinucleotide has Formula I, wherein R 2 is OH and R 3 is O-CH3.
  • the dinucleotide has Formula I, wherein R 2 is O-CH3 and R 3 is OH.
  • the dinucleotide cap analog may preferably have a 3'-O-methyl ribose modification or a 2'-O-methyl ribose modification and may have three, four or five phosphate moieties, i.e., m2 7,3 O GpppN or m2 7,2 '- °GpppN, m2 7,3 O GppppN or m2 7,2 O GppppN, m2 7,3 O GpppppN or rri2 7 ' 2 O GpppppN.
  • B (N) is guanosine
  • the dinucleotide cap analog is an anti-reverse cap analog (ARCA) having the structural formula of m2 7,3 O GpppG also abbreviated as 3'-O-Me-m 7 G(5')pppG(5'):
  • ARCA anti-reverse cap analog
  • the concentration of the dinucleotide cap analog in the reaction mixture is between 0.1 and 100 mM, between 1 and 50 mM, preferably between 1 and 10 mM, and most preferably between 3 and 5 mM.
  • the dinucleotide cap analog is present in the reaction mixture at a concentration of 4 mM.
  • the dinucleotide cap analog is present in the reaction mixture at a concentration of 5 mM.
  • the total rNTP concentration in the reaction mixture is between 1 and 100 mM, preferably between 10 and 50 mM, and most preferably between 15 and 25 mM.
  • the term total ribonucleotide concentration means the total concentration of rNTPs, e.g. the sum of the concentrations of ATP, GTP, CTP, UTP, optionally any modified rNTP and the dinucleotide cap present initially in the reaction when the various components of the reaction have been assembled in the final volume for carrying out the reaction.
  • the nucleotides will be incorporated into the RNA molecule and consequently the total nucleotide concentration will be progressively reduced from its initial value.
  • the concentrations of dinucleotide cap analogs and nucleoside triphosphates present in the IVT reaction can vary, as described for the rNPTs before.
  • the NTP and dinucleotide cap analogs are present in equimolar concentrations in the reaction. That means the molar ratio of dinucleotide cap analog to rNTP is 1:1.
  • the molar ratio of the dinucleotide cap analog to nucleoside triphosphate in the reaction is greater than 1:1.
  • the molar ratio of cap analog to nucleoside triphosphate in the reaction is 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1.
  • the molar ratio of the dinucleotide cap analog to nucleoside triphosphate in the reaction is less than 1:1. In some embodiments, the molar ratio of the dinucleotide cap analog to nucleoside triphosphate in the reaction is less than 4:5. In an embodiment, the molar ratio of the dinucleotide cap analog to nucleoside triphosphate ranges from 1:1 to 8:1. In an embodiment, the molar ratio of the dinucleotide cap analog to nucleoside triphosphate ranges from 0.2:1 to 8:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to ATP is 1:1.
  • the molar ratio of the dinucleotide cap analog to CTP is 1:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to UTP is 1:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to a modified ATP, CTP or UTP is 1:1. In preferred embodiments, the molar ratio of the dinucleotide cap analog to GTP ranges from 1:1 to
  • the dinucleotide cap analog is present at a ratio dinucleotide cap analog to GTP of 4:1.
  • Cap-0 transcripts can be enzymatically converted to cap-1 in vitro.
  • mRNA cap 2'-O-methyltransferase adds a methyl group at the 2'-0 position of the first nucleotide adjacent to the cap structure at the 5' end of the RNA.
  • the enzyme utilizes S-adenosylmethionine (SAM) as a methyl donor to methylate capped RNA (Cap-0) resulting in a Cap-1 structure. It has been reported that such capl structure may result in a higher translational-competency (Kuge et al. (1998) Nucl. Acids Res. 26(13): 3208-3214.) and cellular stability and a reduced activation of cellular pro- inflammatory cytokines, as compared, e.g., to other cap analog structures known in the art.
  • SAM S-adenosylmethionine
  • the 2'-O-methyltransferase is of viral origin. In preferable embodiments, the 2'-O- methyltransferase is derived from a Vaccinia virus. In embodiments, the 2'-O-methyltransferase is a Vaccinia virus cap-specific ribonucleoside 2'-O-methyltransferase, functional mutant, chimera or variant thereof. In an embodiment, 2'-O-methyltransferase is derived from SARS-CoV-2.
  • the 2'-O-methyltransferase is RNA polymerase exhibiting 2'-O-methyltransferase activity (see for example "An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization", Egloff et al., 2002, The EMBO Journal.)
  • the 2'-O-methyltransferase transfers a methyl group from the co-substrate SAM to the target molecule.
  • the concentration of 2'-O-methyltransferase in the final reaction is between 10 and 100 Units.
  • the concentration of 2'-O-methyltransferase in the final reaction is between 25 and 75 Units.
  • the concentration of 2'-O-methyltransferase in the final reaction is about 50 Units.
  • the concentration of 2'-O-methyltransferase in the final reaction is 50 Units.
  • SAM S-adenosylmethionine
  • S-adenosylmethionine As used herein, "S-adenosylmethionine”, “S-Adenosyl-L-methionine”, “SAM”, and “AdoMet” are used interchangeably and refer to a compound having formula C15H22N6O5.
  • the 2'-O-methyltransferase transfers a methyl group from the co-substrate S-adenosyl-L-methionine to first nucleotide adjacent to the cap structure at the 5' end of the mRNA.
  • the concentration of S-adenosylmethionine in the final reaction is between 0.05 and ImM.
  • the concentration of S-adenosylmethionine in the final reaction is 0.2-0.3 mM.
  • the concentration of S-adenosylmethionine in the final reaction is about 0.25 mM. In preferred embodiments, the concentration of S-adenosylmethionine in the final reaction is 0.25 mM.
  • the composition optionally further comprises a poly(A) polymerase.
  • a poly(A) tail may also be added post transcriptionally by enzymatic polyadenylation using a poly(A) polymerase.
  • Poly(A) polymerase catalyzes the templateindependent addition of AMP from ATP to the 3' end of RNA.
  • a poly(A) tail may contain 10 to 300 adenosine monophosphates.
  • a poly(A) tail may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates.
  • a poly(A) tail contains 50 to 170 adenosine monophosphates.
  • the poly(A) tail contains between 120 and 150 adenosine monophosphates, preferably 120 adenosine monophosphates.
  • the poly(A) polymerase may be modified or unmodified.
  • the modified or unmodified poly(A) polymerase is of bacterial origin.
  • the modified or unmodified poly(A) polymerase is derived from Escherichia coll.
  • the present composition may also be provided as a stock composition, which may be diluted shortly before usage.
  • the composition is suitable for long term storage.
  • the composition is stable for about 1-10 days, including 1 day including 5-24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 1-5 months, 1-6 months.
  • the composition being stable means that the components are still reactive and a reaction can be initiated after the time of storage with no significant loss of product yield.
  • the composition is stored at appropriate temperatures, comprising temperatures below 8°C.
  • composition for synthesis of mRNA therapeutics.
  • composition of the invention disclosed herein may be used for synthesis of mRNA therapeutics.
  • mRNA therapeutics comprise compositions for treating cancer. In an embodiment, mRNA therapeutics comprise compositions for treating and/or prevention of infectious disease. In an embodiment, mRNA therapeutics comprise an infectious disease vaccine. In an embodiment, mRNA therapeutics comprise compositions for allergy tolerization. In an embodiment, mRNA therapeutics comprise compositions for protein replacement therapy.
  • mRNA therapeutics delivery is enhanced by LNPs, polymeric nanoparticles, cationic nanoemulsions or other delivery systems (see for example Qin, S., Tang, X., Chen, Y. et al., mRNA-based therapeutics: powerful and versatile tools to combat diseases, Sig Transduct Target Ther 7, 166 (2022)).
  • composition in a bioreactor for RNA in vitro transcription
  • composition according to the invention disclosed herein may be used in a bioreactor for mRNA production.
  • a bioreactor allows for repetitive use of DNA templates in several RNA production processes.
  • DNA templates are immobilized on solid support.
  • composition of the invention By using the composition of the invention, mRNA manufacturing is accelerated since all reaction components are present in only one vessel. This decreases the risk of contamination and saves time in adjusting the reaction settings.
  • a bioreactor is preferably suitable for a use under regulated conditions (GMP) and suitable for pharmaceutical applications (e.g. pharmaceutical mRNA production).
  • the bioreactor may allow a continuous production or repeated batch production of a liquid mRNA composition.
  • Exemplary bioreactors are described in W02020002598 Al, W02022261050A1 or WO2022081519 Al.
  • the bioreactor is an automated system, such as an RNA printerTM (see, for example WO2019122371, W02020002598 Al or Sheridan, C., mRNA printers kick-start personalized medicines for all, Nat Biotechnol 40, 1160-1162 (2022)).
  • an RNA printerTM see, for example WO2019122371, W02020002598 Al or Sheridan, C., mRNA printers kick-start personalized medicines for all, Nat Biotechnol 40, 1160-1162 (2022)).
  • composition according to the invention disclosed herein may be used in a continuous flow device or flow reactor for mRNA production.
  • Methods of continuous flow in vitro transcription are described e.g., in EP1165826 Bl, US20230265477 Al or references therein.
  • composition of the invention By using the composition of the invention, mRNA manufacturing is accelerated since all reaction components are present in only one vessel. This decreases the risk of contamination and saves time in adjusting the reaction settings.
  • a continuous flow device is preferably suitable for a use under regulated conditions (GMP) and suitable for pharmaceutical applications (e.g. pharmaceutical mRNA production).
  • the continuous flow device may allow for a continuous production or repeated batch production of a liquid mRNA composition.
  • mRNA is continuously synthesized, while the mRNA product is removed from the flow chamber and a fresh composition according to the invention is flowing into the flow chamber.
  • Exemplary continuous flow devices are described in US20200340028 or US20230265476.
  • method of present invention can be used in bioreactors for continuous or semi-batch process for synthesizing RNA molecules.
  • the bioreactor contains immobilized DNA used as a template for the transcription reaction.
  • the immobilization of the DNA template allows a repeated usage of the template and reduces the contamination of the desired RNA product by residual DNA.
  • required reaction components such as enzymes, SAM, NTPs, reaction buffer, etc., may be supplied to the bioreactor.
  • the produced RNA molecules can be released batch by batch or continuously to be captured and separated from other soluble components of the transcription reaction and to be moved into other compartments of the bioreactor for purification and other processing.
  • the experimental system was based on synthesizing a 25 nt RNA molecule from a linearized template pDNA (pTZ19R (Thermo Scientific cat. no. SD0141) digested with Hindi restriction endonuclease (Thermo Scientific cat. no. FD0494)).
  • pTZ19R Thermo Scientific cat. no. SD0141
  • Hindi restriction endonuclease Thermo Scientific cat. no. FD0494
  • the concentration of the reaction components wase the same.
  • the IVT reaction was performed in lx MessageMachineTM buffer as the transcription buffer (Thermo Scientific cat. no. AM1344) containing 35 ng/pL of the pTZ19R/Hincll template.
  • ATP, CTP, and UTP were added to a final concentration of 5 mM each, and GTP was added at 1 mM.
  • a dinucleotide cap analog here ARCA, Thermo Scientific cat. no. AM8045 was added at a final concentration of 4 mM, yielding a GTP-ARCA ratio of 1:4.
  • IVT reaction was performed in lx MessageMachineTM buffer as the transcription buffer (Thermo Scientific cat. no. AM1344) containing 35 ng/pL of the pTZ19R/Hincll template. ATP, CTP, and UTP were added to a final concentration of 5 mM, and GTP was added at 1 mM. A dinucleotide cap analog (ARCA, Thermo Scientific cat. no. AM8045) was added at a final concentration of 4 mM, yielding a GTP-ARCA ratio of 1:4. T7 RNA polymerase was added as a last component, in the form of Message MachineTM T7 Enzyme Mix (Thermo Scientific cat. no. AM1344). This master mix contained RNase inhibitor, and the reaction was incubated at 37 °C for 2 hours.
  • MessageMachineTM buffer as the transcription buffer (Thermo Scientific cat. no. AM1344) containing 35 ng/pL of the pTZ19R/Hincll
  • the generated capped mRNA was purified enzymatically.
  • the first step was to use the RNA polyphosphatase (BioSearch Technologies cat. no. RP8092H) according to the manufacturer's recommendations to convert 5' triphosphates of uncapped mRNA molecules into monophosphates.
  • the purification was performed using CollibriTM DNA Library Cleanup Kit (Thermo Scientific cat. no. A38584096) according to manufacturer's recommendations on purifying RNA.
  • RNA 2'0- methyltransferase (20Mt, Thermo Fisher Scientific) was added to the purified mRNA to a final concentration of 2.5 U/pL and S-adenosyl methionine (SAM, Thermo Scientific) to a final concentration of 0.25 mM.
  • SAM S-adenosyl methionine
  • the reaction was incubated at 37 °C for one hour.
  • the purification was performed using CollibriTM DNA Library Cleanup Kit (Thermo Scientific cat. no. A38584096) according to manufacturer's recommendations on purifying RNA. Integrity of mRNA as well as capping efficiency is confirmed by mass spectrometry as provided in Figs. 1-5.
  • the Add-on reaction was performed similarly to the Sequential reaction, however, without purifying the capped mRNA as an intermediate step.
  • the 2'0-methyltransferase and the S-adenosyl methionine (SAM) were directly added to the IVT reaction after capping reaction has been completed.
  • the IVT reaction was performed in lx MessageMachineTM buffer as the transcription buffer (Thermo Scientific cat. no. AM1344) containing 35 ng/pL of the pTZ19R/Hincll template. ATP, CTP, and UTP were added to a final concentration of 5 mM, and GTP was added at 1 mM. A dinucleotide cap analog (ARCA, Thermo Scientific cat. no. AM8045) was added at a final concentration of 4 mM, yielding a GTP-ARCA ratio of 1:4.
  • the reaction additionally comprised 2'0-methyltransferase (2OMt, Thermo Fisher Scientific) to a final concentration of 2.5 U/pL and S-adenosyl methionine (SAM, Thermo Scientific) to a final concentration of 0.25 mM.
  • 2OMt 2'0-methyltransferase
  • SAM S-adenosyl methionine
  • T7 RNA polymerase was added last in the form of Message Machine T7 Enzyme Mix (Thermo Scientific cat. no. AM1344) to initiate the reaction, which was incubated at 37 °C for 2 hours.
  • This master mix contained RNase inhibitor.
  • reaction products were purified using magnetic bead clean-up kit (Thermo Scientific cat. no. A43190024) according to the manufacturer's instructions.
  • Example 1 Resulting products obtained in Example 1 were analyzed using capillary electrophoresis and then subject to LC-MS analysis.
  • Liquid chromatography was carried out on a Vanquish Horizon UHPLC System using two-phase separation (mobile phase A: 10 mM triethylamine+100 mM hexafluoroisopropanol; mobile phase B: 1:1 mobile phase A+methanol) on a DNAPac HPLC column (4 pm, 2.1x100 mm, Thermo Scientific cat. no. 088923).
  • Mass spectrometry was carried out on a Q ExactiveTM Plus Hybrid Quadrupole-OrbitrapTM Mass Spectrometer (Thermo Scientific). Results are represented in FIG 1-5.
  • RNA vs ARCA-RNA The reaction products were detected as m/z values described in FIGS 1-5.
  • Fig. 1 RNA vs ARCA-RNA. Top spectrum depicts the distinct peaks characteristic of ARCA-capped 26 nt mRNA. Bottom spectrum depicts the characteristic peaks of the same 25 nt mRNA molecule without ARCA. The highlighted m/z difference between species is 293, corresponding to ARCA molecular weight.
  • Fig. 2 ARCA-RNA vs 2'-OMe-ARCA-RNA.
  • Top spectrum depicts ARCA-RNA with its characteristic m/z 8887 (only single charge species are observed herein).
  • Bottom spectrum shows an m/z peak at 8901, an increase of m/z 14 corresponding to a methyl group.
  • Fig. 3 ARCA-RNA vs 2'-OMe-ARCA-RNA from sequential reaction.
  • Top spectrum depicts ARCA-RNA with its characteristic m/z 8887 (only single charge species are observed herein).
  • Bottom spectrum shows an m/z peak at 8901, an increase of m/z 14 corresponding to a methyl group.
  • Fig. 4 ARCA-RNA vs 2'-OMe-ARCA-RNA from add-on reaction.
  • Top spectrum depicts ARCA-RNA with its characteristic m/z 8887 (only single charge species are observed herein).
  • Bottom spectrum shows an m/z peak at 8901, an increase of m/z 14 corresponding to a methyl group.
  • Fig. 5 ARCA-RNA vs 2'-OMe-ARCA-RNA from one-pot reaction. Top spectrum depicts ARCA-RNA with its characteristic m/z 8887 (only single charge species are observed herein). Bottom spectrum shows an m/z peak at 8901, an increase of m/z 14 corresponding to a methyl group.
  • capped mRNA having a capl structure could be achieved with the one-pot system containing the co-transcriptional IVT mix added with 2OMt and SAM.
  • Relative abundances from mass spectrum offered representative data depicted in FIG 7.
  • the capping efficiency corresponds to the values observed in the literature.
  • Capped fraction equals to the capping efficiency, corresponding to the produced ARCA-RNA.
  • 100% methylation efficiency is observed, as no unmethylated species are observed in the mass spectrum (fig. 5).
  • the capped, methylated fraction is therefore equal to the capping efficiency, as 100% of cap is methylated.
  • the results are concurrent with ARCA capping efficiency (%Cap) reported in literature, additionally demonstrating 100% methylation efficiency.
  • the present invention allows to obtain a cap-1 structure on the nascent mRNA molecules by having a 2'0-methyltransferase and SAM present in the reaction. Such effect presents the means to obtain an mRNA moiety more readily suitable for direct transfection with potentially better outcomes.
  • reaction with NEB 2OMt enzyme is denoted "competitor”
  • Capping efficiency (%) pertains to the mass spectrometry data, i.e., the ratio of RNA and ARCA-RNA species.
  • ARCA methylation (%) pertains to mass spectrometry data, i.e., the ratio of ARCA-RNA and 2'-0Me-ARCA-RNA.
  • highest capping and ARCA methylation efficiency was achieved in One-pot reaction workflow settings.

Landscapes

  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé et une composition pour synthétiser un ARNm coiffé dans des conditions permettant un coiffage d'ARNm co-transcriptionnel et une méthylation d'ARNm coiffé dans la même réaction, générant ainsi un ARNm coiffé synthétisé, l'ARNm coiffé synthétisé ayant une structure de type cap1.
PCT/EP2025/062232 2024-05-06 2025-05-05 Utilisation d'arca et d'enzyme 2'o-méthyl transférase pour produire une structure cap1 d'une coiffe d'arnm 5' Pending WO2025233286A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2406294.5A GB202406294D0 (en) 2024-05-06 2024-05-06 Methods and compositions for producing capped mRNA
GB2406294.5 2024-05-06

Publications (2)

Publication Number Publication Date
WO2025233286A2 true WO2025233286A2 (fr) 2025-11-13
WO2025233286A3 WO2025233286A3 (fr) 2026-03-12

Family

ID=91248230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/062232 Pending WO2025233286A2 (fr) 2024-05-06 2025-05-05 Utilisation d'arca et d'enzyme 2'o-méthyl transférase pour produire une structure cap1 d'une coiffe d'arnm 5'

Country Status (2)

Country Link
GB (1) GB202406294D0 (fr)
WO (1) WO2025233286A2 (fr)

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008626A1 (fr) 1993-09-20 1995-03-30 The Regents Of The University Of Colorado Strategie de production d'arn a partir de matrices immobilisees
EP1165826B1 (fr) 1999-03-25 2006-12-06 Roche Diagnostics GmbH Technique permettant de synthetiser des polypeptides dans des systemes acellulaires
WO2010016621A1 (fr) 2008-08-08 2010-02-11 東ソー株式会社 Mutant d’arn polymérase ayant des fonctions améliorées
WO2013052523A1 (fr) 2011-10-03 2013-04-11 modeRNA Therapeutics Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
WO2016193226A1 (fr) 2015-05-29 2016-12-08 Curevac Ag Procédé d'ajout de structures de coiffe à un arn au moyen d'enzymes immobilisées
WO2017062343A1 (fr) 2015-10-06 2017-04-13 Pierce Biotechnology, Inc. Dispositifs et procédés de production d'acides nucléiques et de protéines
WO2017123748A1 (fr) 2016-01-13 2017-07-20 New England Biolabs, Inc. Variants thermostables d'arn polymérase t7
WO2018236617A1 (fr) 2017-06-21 2018-12-27 New England Biolabs, Inc. Utilisation d'arn polymérases thermostables pour produire des arn à immunogénicité réduite
WO2019005540A1 (fr) 2017-06-30 2019-01-03 Codexis, Inc. Variants d'arn polymérase t7
WO2019005539A1 (fr) 2017-06-30 2019-01-03 Codexis, Inc. Variants d'arn polymérase t7
WO2019122371A1 (fr) 2017-12-21 2019-06-27 Curevac Ag Adn linéaire double brin couplé à un support ou une étiquette unique et procédés de production dudit adn linéaire double brin
WO2019199807A1 (fr) 2018-04-10 2019-10-17 Greenlight Biosciences, Inc. Variants d'arn polymérase t7
WO2020002598A1 (fr) 2018-06-28 2020-01-02 Curevac Ag Bioréacteur pour transcription in vitro d'arn
US20200340028A1 (en) 2019-04-24 2020-10-29 The University Of Massachusetts Novel enzymatic methods to generate high yields of sequence specific rna oligonucleotides with extreme precision
CN112831484A (zh) 2021-01-13 2021-05-25 华中科技大学 T7-rna聚合酶突变体及其应用
US11066686B2 (en) 2017-08-18 2021-07-20 Modernatx, Inc. RNA polymerase variants
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
WO2022081519A1 (fr) 2020-10-12 2022-04-21 Life Technologies As Systèmes de traitement de particules magnétiques destinés à être utilisés avec des cellules biologiques et procédés associés
US11485960B2 (en) 2019-02-20 2022-11-01 Modernatx, Inc. RNA polymerase variants for co-transcriptional capping
WO2022261050A1 (fr) 2021-06-07 2022-12-15 The University Of Massachusetts Appareil et procédé de production continue d'arn
US20230265476A1 (en) 2020-05-12 2023-08-24 Charalampos Makatsoris A method and modular apparatus for the synthesis of rna-based therapeutics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120082614A (zh) * 2019-08-23 2025-06-03 新英格兰生物实验室公司 酶促rna加帽方法
WO2023173098A1 (fr) * 2022-03-11 2023-09-14 New England Biolabs, Inc. Compositions d'enzymes immobilisées et méthodes associées

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008626A1 (fr) 1993-09-20 1995-03-30 The Regents Of The University Of Colorado Strategie de production d'arn a partir de matrices immobilisees
EP1165826B1 (fr) 1999-03-25 2006-12-06 Roche Diagnostics GmbH Technique permettant de synthetiser des polypeptides dans des systemes acellulaires
WO2010016621A1 (fr) 2008-08-08 2010-02-11 東ソー株式会社 Mutant d’arn polymérase ayant des fonctions améliorées
WO2013052523A1 (fr) 2011-10-03 2013-04-11 modeRNA Therapeutics Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
WO2016193226A1 (fr) 2015-05-29 2016-12-08 Curevac Ag Procédé d'ajout de structures de coiffe à un arn au moyen d'enzymes immobilisées
WO2017062343A1 (fr) 2015-10-06 2017-04-13 Pierce Biotechnology, Inc. Dispositifs et procédés de production d'acides nucléiques et de protéines
WO2017123748A1 (fr) 2016-01-13 2017-07-20 New England Biolabs, Inc. Variants thermostables d'arn polymérase t7
WO2018236617A1 (fr) 2017-06-21 2018-12-27 New England Biolabs, Inc. Utilisation d'arn polymérases thermostables pour produire des arn à immunogénicité réduite
WO2019005540A1 (fr) 2017-06-30 2019-01-03 Codexis, Inc. Variants d'arn polymérase t7
WO2019005539A1 (fr) 2017-06-30 2019-01-03 Codexis, Inc. Variants d'arn polymérase t7
US11066686B2 (en) 2017-08-18 2021-07-20 Modernatx, Inc. RNA polymerase variants
WO2019122371A1 (fr) 2017-12-21 2019-06-27 Curevac Ag Adn linéaire double brin couplé à un support ou une étiquette unique et procédés de production dudit adn linéaire double brin
WO2019199807A1 (fr) 2018-04-10 2019-10-17 Greenlight Biosciences, Inc. Variants d'arn polymérase t7
WO2020002598A1 (fr) 2018-06-28 2020-01-02 Curevac Ag Bioréacteur pour transcription in vitro d'arn
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
US11485960B2 (en) 2019-02-20 2022-11-01 Modernatx, Inc. RNA polymerase variants for co-transcriptional capping
US20200340028A1 (en) 2019-04-24 2020-10-29 The University Of Massachusetts Novel enzymatic methods to generate high yields of sequence specific rna oligonucleotides with extreme precision
US20230265477A1 (en) 2019-04-24 2023-08-24 University Of Massachusetts Novel enzymatic methods to generate high yields of sequence specific rna oligonucleotides with extreme precision
US20230265476A1 (en) 2020-05-12 2023-08-24 Charalampos Makatsoris A method and modular apparatus for the synthesis of rna-based therapeutics
WO2022081519A1 (fr) 2020-10-12 2022-04-21 Life Technologies As Systèmes de traitement de particules magnétiques destinés à être utilisés avec des cellules biologiques et procédés associés
CN112831484A (zh) 2021-01-13 2021-05-25 华中科技大学 T7-rna聚合酶突变体及其应用
WO2022261050A1 (fr) 2021-06-07 2022-12-15 The University Of Massachusetts Appareil et procédé de production continue d'arn

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ARNDT-JOVIN ET AL., EUR. J. BIOCHEM., vol. 54, no. 2, 1975, pages 1 - 8
BAR ET AL., LANGMUIR, vol. 12, 1996, pages 1172
BETHELL ET AL., J. ELECTROANAL. CHEM., vol. 409, 1996, pages 137
CAZENAVE CUHLENBECK OC: "RNA Template-Directed RNA Synthesis by T7 RNA Polymerase", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 6972 - 6976, XP002049779, DOI: 10.1073/pnas.91.15.6972
COLVIN ET AL., J. AM. CHEM. SOC., vol. 114, 1992, pages 5221
EGLOFF ET AL., THE EMBO JOURNAL, 2002
GRABAR ET AL., ANALYT. CHEM., vol. 67, 1995, pages 73 - 743
KERN ET AL., BIOTECHNOL. PROG., vol. 13, 1997, pages 747 - 756
KERN ET AL., BIOTECHNOL. PROG., vol. 15, 1999, pages 174 - 184
KERRIGAN ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vol. 24, 2001
KUGE ET AL., NUCL. ACIDS RES., vol. 26, no. 13, 1998, pages 3208 - 3214
LEGNINI, I.ALLES, J.KARAISKOS, N. ET AL.: "FLAM-seq: full-length mRNA sequencing reveals principles of poly(A) tail length control", NAT METHODS, vol. 16, 2019, pages 879 - 886, XP036954228, DOI: 10.1038/s41592-019-0503-y
MUTTACH ET AL., J. ORG CHEM., vol. 13, 2017, pages 2819 - 2832
PERZANOWSKA O. ET AL.: "Chemically Modified Poly(A) Analogs Targeting PABP: Structure Activity Relationship and Translation Inhibitory Properties", CHEMISTRY - A EUROPEAN JOURNAL, vol. 28, 2022, pages e202201115
QIN, S.TANG, X.CHEN, Y. ET AL.: "mRNA-based therapeutics: powerful and versatile tools to combat diseases", SIG TRANSDUCT TARGET THER, vol. 7, 2022, pages 166
SHERIDAN, C.: "mRNA printers kick-start personalized medicines for all", NAT BIOTECHNOL, vol. 40, 2022, pages 1160 - 1162, XP038003097, DOI: 10.1038/s41587-022-01430-y
STRZELECKA D. ET AL., RNA, vol. 26, no. 12, December 2020 (2020-12-01), pages 1815 - 1837

Also Published As

Publication number Publication date
GB202406294D0 (en) 2024-06-19
WO2025233286A3 (fr) 2026-03-12

Similar Documents

Publication Publication Date Title
EP3317424B1 (fr) Procédé d'analyse d'une molécule d'arn
AU2014375404C1 (en) Methods for RNA analysis
US11920174B2 (en) RNA analysis by total hydrolysis and quantification of released nucleosides
EP3155129B1 (fr) Procédé d'amélioration de la production d'arn
EP3090060B2 (fr) Procédés d'analyse d'arn
JP2025509962A (ja) シュードウリジン三リン酸を酵素的に生産する方法及び組成物
WO2025233286A2 (fr) Utilisation d'arca et d'enzyme 2'o-méthyl transférase pour produire une structure cap1 d'une coiffe d'arnm 5'
EP4728063A1 (fr) Procédés d'identification ou de quantification simultanée de modifications de coiffage et de queue d'arn messager
WO2024170684A1 (fr) Criblage de séquences nucléotiques avec optimisation des codons
CN118786215A (zh) 使用催化性核酸分析rna分子
US11898186B1 (en) Compositions and methods for preparing capped mRNA
EP4638772A2 (fr) Queue optimisée d'arn messager
Strzelecka et al. Functional and LC-MS/MS analysis of in vitro transcribed mRNAs carrying phosphorothioate or boranophosphate moieties reveal polyA tail modifications that prevent deadenylation without compromising protein expression
WO2024184489A1 (fr) Fabrication d'arn messager avec kp34 polymérase
WO2026015876A1 (fr) Méthodes améliorées de transcription in vitro

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25723697

Country of ref document: EP

Kind code of ref document: A2